CN107474004A - 三氟甲基季碳中心化合物及其制备方法和应用 - Google Patents
三氟甲基季碳中心化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN107474004A CN107474004A CN201610402650.8A CN201610402650A CN107474004A CN 107474004 A CN107474004 A CN 107474004A CN 201610402650 A CN201610402650 A CN 201610402650A CN 107474004 A CN107474004 A CN 107474004A
- Authority
- CN
- China
- Prior art keywords
- compound
- trifluoromethyl
- quaternary carbon
- carbon center
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 92
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 title claims abstract description 65
- 229910052799 carbon Inorganic materials 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 238000006243 chemical reaction Methods 0.000 claims abstract description 60
- 240000008067 Cucumis sativus Species 0.000 claims abstract description 25
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims abstract description 25
- 241000209140 Triticum Species 0.000 claims abstract description 16
- 235000021307 Triticum Nutrition 0.000 claims abstract description 16
- 241000221785 Erysiphales Species 0.000 claims abstract description 15
- 241000233679 Peronosporaceae Species 0.000 claims abstract description 14
- 240000008042 Zea mays Species 0.000 claims abstract description 14
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 14
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 14
- 235000005822 corn Nutrition 0.000 claims abstract description 14
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 56
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- 239000003054 catalyst Substances 0.000 claims description 30
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 claims description 26
- -1 methoxyl group Chemical group 0.000 claims description 24
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 21
- 229940125904 compound 1 Drugs 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical group 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000003960 organic solvent Substances 0.000 claims description 16
- 241000196324 Embryophyta Species 0.000 claims description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 150000004696 coordination complex Chemical group 0.000 claims description 11
- 229910052740 iodine Inorganic materials 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 10
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 125000003944 tolyl group Chemical group 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 229940125782 compound 2 Drugs 0.000 claims description 5
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 claims description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 2
- 229940126214 compound 3 Drugs 0.000 claims description 2
- 229940125898 compound 5 Drugs 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims description 2
- ZRNSSRODJSSVEJ-UHFFFAOYSA-N 2-methylpentacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(C)C ZRNSSRODJSSVEJ-UHFFFAOYSA-N 0.000 claims 2
- 241000219112 Cucumis Species 0.000 claims 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N monofluoromethane Natural products FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims 2
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000003610 charcoal Substances 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 304
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 51
- 238000004293 19F NMR spectroscopy Methods 0.000 description 51
- 238000005160 1H NMR spectroscopy Methods 0.000 description 51
- 239000007788 liquid Substances 0.000 description 45
- 229910014263 BrF3 Inorganic materials 0.000 description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 239000011734 sodium Substances 0.000 description 22
- 0 CCC(C)C(CC)*(*C)C(CC*(C)=C)=N Chemical compound CCC(C)C(CC)*(*C)C(CC*(C)=C)=N 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QMGHHBHPDDAGGO-IIWOMYBWSA-N (2S,4R)-1-[(2S)-2-[[2-[3-[4-[3-[4-[[5-bromo-4-[3-[cyclobutanecarbonyl(methyl)amino]propylamino]pyrimidin-2-yl]amino]phenoxy]propoxy]butoxy]propoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide Chemical compound CN(CCCNC1=NC(NC2=CC=C(OCCCOCCCCOCCCOCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C=C3)C3=C(C)N=CS3)C(C)(C)C)C=C2)=NC=C1Br)C(=O)C1CCC1 QMGHHBHPDDAGGO-IIWOMYBWSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 2
- 240000006995 Abutilon theophrasti Species 0.000 description 2
- 241000272639 Brachycaudus mimeuri Species 0.000 description 2
- 244000058871 Echinochloa crus-galli Species 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 241000409991 Mythimna separata Species 0.000 description 2
- 244000115721 Pennisetum typhoides Species 0.000 description 2
- 235000007195 Pennisetum typhoides Nutrition 0.000 description 2
- 235000008515 Setaria glauca Nutrition 0.000 description 2
- JXASPPWQHFOWPL-UHFFFAOYSA-N Tamarixin Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 JXASPPWQHFOWPL-UHFFFAOYSA-N 0.000 description 2
- 241000344246 Tetranychus cinnabarinus Species 0.000 description 2
- 240000003307 Zinnia violacea Species 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000749 insecticidal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000009333 weeding Methods 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- GNPHAOQLHRZODS-ZQWQDMLBSA-N (1s,2s,3s,4s)-3,4-bis[butyl-[(4-phenoxyphenyl)methyl]carbamoyl]cyclobutane-1,2-dicarboxylic acid Chemical compound O=C([C@H]1[C@@H]([C@@H]([C@H]1C(O)=O)C(O)=O)C(=O)N(CCCC)CC=1C=CC(OC=2C=CC=CC=2)=CC=1)N(CCCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 GNPHAOQLHRZODS-ZQWQDMLBSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- IZGDXVLRMHXOJV-SFHVURJKSA-N (3s)-4-[2-[2-(4-fluoro-3-methylphenyl)-4-methyl-6-propan-2-ylphenyl]ethyl-hydroxyphosphoryl]-3-hydroxybutanoic acid Chemical compound CC(C)C1=CC(C)=CC(C=2C=C(C)C(F)=CC=2)=C1CCP(O)(=O)C[C@@H](O)CC(O)=O IZGDXVLRMHXOJV-SFHVURJKSA-N 0.000 description 1
- WHQUHTXULUACFD-KRWDZBQOSA-N (3s)-4-[[2-(4-fluoro-3-methylphenyl)-4-methyl-6-propan-2-ylphenyl]methoxy-hydroxyphosphoryl]-3-hydroxybutanoic acid Chemical compound CC(C)C1=CC(C)=CC(C=2C=C(C)C(F)=CC=2)=C1COP(O)(=O)C[C@@H](O)CC(O)=O WHQUHTXULUACFD-KRWDZBQOSA-N 0.000 description 1
- AXQACEQYCPKDMV-RZAWKFBISA-N (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-n-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3C(O)=C(C[C@]2(O)[C@]34CC1)C(=O)NC(C)(C)C=1ON=C(N=1)C=1C=CC=CC=1)CC1CC1 AXQACEQYCPKDMV-RZAWKFBISA-N 0.000 description 1
- MNIPVWXWSPXERA-IDNZQHFXSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecanoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)CCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 MNIPVWXWSPXERA-IDNZQHFXSA-N 0.000 description 1
- JENUMEXEVAAAJX-SNVBAGLBSA-N 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-1-[(2r)-2-methyl-4-[2-(trifluoromethyl)-4-[2-(trifluoromethyl)pyrimidin-5-yl]-1,3-thiazol-5-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1C)N(C2=C(N=C(S2)C(F)(F)F)C=2C=NC(=NC=2)C(F)(F)F)CCN1C(=O)CN1N=C(C)N=C1C JENUMEXEVAAAJX-SNVBAGLBSA-N 0.000 description 1
- IOOWNWLVCOUUEX-WPRPVWTQSA-N 2-[(3r,6s)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid Chemical compound OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1 IOOWNWLVCOUUEX-WPRPVWTQSA-N 0.000 description 1
- PPSMYAUEJRADFE-HXUWFJFHSA-N 2-[(5r)-4-[2-[3-(6-methylpyridin-3-yl)oxyphenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid Chemical compound C1=NC(C)=CC=C1OC1=CC=CC(CC(=O)N2[C@@H](C3=CC=C(N=C3NCC2)C(F)(F)F)CC(O)=O)=C1 PPSMYAUEJRADFE-HXUWFJFHSA-N 0.000 description 1
- PSWDQTMAUUQILQ-UHFFFAOYSA-N 2-[(6-methoxy-4-methylquinazolin-2-yl)amino]-5,6-dimethyl-1h-pyrimidin-4-one Chemical compound N1=C(C)C2=CC(OC)=CC=C2N=C1NC1=NC(=O)C(C)=C(C)N1 PSWDQTMAUUQILQ-UHFFFAOYSA-N 0.000 description 1
- JGMXNNSYEFOBHQ-OWOJBTEDSA-N 2-[(e)-4-morpholin-4-ylbut-2-enyl]-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)C=2SC(S(=O)(=O)N)=CC=2C=CN1C\C=C\CN1CCOCC1 JGMXNNSYEFOBHQ-OWOJBTEDSA-N 0.000 description 1
- KKKJYDOHVKIIQP-UHFFFAOYSA-N 2-[4-(3-chlorobenzoyl)phenoxy]-N-pyridin-3-ylacetamide Chemical compound ClC=1C=C(C(=O)C2=CC=C(OCC(=O)NC=3C=NC=CC=3)C=C2)C=CC=1 KKKJYDOHVKIIQP-UHFFFAOYSA-N 0.000 description 1
- LHASZEBEQGPCFM-CJFMBICVSA-N 2-amino-4-[(1r)-1-[[(6r)-6-[(5-chloro-2-methoxyphenyl)methyl]-7-oxo-3-(phenoxyamino)-5,6-dihydro-2h-1,4-diazepine-1-carbonyl]amino]propyl]benzoic acid Chemical compound C([C@@H]1CNC(CN(C1=O)C(=O)N[C@H](CC)C=1C=C(N)C(C(O)=O)=CC=1)=NOC=1C=CC=CC=1)C1=CC(Cl)=CC=C1OC LHASZEBEQGPCFM-CJFMBICVSA-N 0.000 description 1
- DNTVJEMGHBIUMW-IBGZPJMESA-N 3-[[4-[(1s)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)pyrazol-1-yl]ethyl]benzoyl]amino]propanoic acid Chemical compound C1([C@H](C)N2N=C(C=C2C2=CC3=CC=C(C=C3C=C2)OC)C=2C=C(Cl)C=C(Cl)C=2)=CC=C(C(=O)NCCC(O)=O)C=C1 DNTVJEMGHBIUMW-IBGZPJMESA-N 0.000 description 1
- GOAKYBVMJUXOFY-LBPRGKRZSA-N 3-amino-4-[(3S)-3-(2-ethoxyethoxymethyl)piperidin-1-yl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound CCOCCOC[C@@H](CCC1)CN1C1=C(C(N)=C(C(N)=O)S2)C2=NC=C1 GOAKYBVMJUXOFY-LBPRGKRZSA-N 0.000 description 1
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 1
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 1
- DJSWNINDPRRCLC-GOSISDBHSA-N 7-methyl-n-[(2r)-1-phenoxypropan-2-yl]-3-(4-propan-2-ylphenyl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound C([C@@H](C)NC(=O)C1=C(N2N=CC(=C2N=C1)C=1C=CC(=CC=1)C(C)C)C)OC1=CC=CC=C1 DJSWNINDPRRCLC-GOSISDBHSA-N 0.000 description 1
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 1
- UFMQJYHLIUACCG-UHFFFAOYSA-N 8-nitroindolo[2,1-b]quinazoline-6,12-dione Chemical compound C1=CC=C2C(=O)N3C4=CC=C([N+](=O)[O-])C=C4C(=O)C3=NC2=C1 UFMQJYHLIUACCG-UHFFFAOYSA-N 0.000 description 1
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229940126650 Compound 3f Drugs 0.000 description 1
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 1
- AKQOBHZKBDHWQI-BZEFIUHZSA-N O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O Chemical compound O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O AKQOBHZKBDHWQI-BZEFIUHZSA-N 0.000 description 1
- 241000500437 Plutella xylostella Species 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229940125796 compound 3d Drugs 0.000 description 1
- 229940127108 compound 5g Drugs 0.000 description 1
- 229940126136 compound 5i Drugs 0.000 description 1
- 229940125801 compound 7f Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006115 defluorination reaction Methods 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- MUTCAPXLKRYEPR-ITWZMISCSA-N methyl (e,3r,5s)-7-[4-bromo-2,3-bis(4-fluorophenyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyhept-6-enoate Chemical compound COC(=O)C[C@H](O)C[C@H](O)\C=C\N1C(C(C)C)=C(Br)C(C=2C=CC(F)=CC=2)=C1C1=CC=C(F)C=C1 MUTCAPXLKRYEPR-ITWZMISCSA-N 0.000 description 1
- PSBGROLQRNSAMY-UHFFFAOYSA-N n-(3-chlorophenyl)-4-methyl-3-(2-pyrazolo[1,5-a]pyrimidin-6-ylethynyl)benzamide Chemical compound C1=C(C#CC2=CN3N=CC=C3N=C2)C(C)=CC=C1C(=O)NC1=CC=CC(Cl)=C1 PSBGROLQRNSAMY-UHFFFAOYSA-N 0.000 description 1
- JBLLRCOZJMVOAE-HSQYWUDLSA-N n-[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methoxy-1h-indole-2-carboxamide Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)C=1NC=2C=CC=C(C=2C=1)OC)C(=O)C=1SC2=CC=CC=C2N=1)[C@@H]1CCNC1=O JBLLRCOZJMVOAE-HSQYWUDLSA-N 0.000 description 1
- RCSBCWXPGSPJNF-UHFFFAOYSA-N n-[4-[5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]butyl]-4-(1,8-naphthyridin-2-yl)butanamide Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC=C1C(O1)=NN=C1CCCCNC(=O)CCCC1=CC=C(C=CC=N2)C2=N1 RCSBCWXPGSPJNF-UHFFFAOYSA-N 0.000 description 1
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/46—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom rings with more than six members
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/76—1,3-Oxazoles; Hydrogenated 1,3-oxazoles
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dentistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明公开了三氟甲基季碳中心化合物及其制备方法和应用。该三氟甲基季碳中心化合物如式3或3’所示。本发明的制备方法简单、反应收率高,得到的三氟甲基季碳中心化合物有较强的生物活性,对玉米锈病、黄瓜霜霉病、小麦白粉病和黄瓜炭疽病具有一定的防治效果。
Description
技术领域
本发明涉及一种三氟甲基季碳中心化合物及其制备方法和应用。
背景技术
由于三氟甲基的独特性质,将三氟甲基引入到分子中通常能增强分子的脂溶性、提高生物利用度和代谢稳定性等,因此,含三氟甲基的化合物被广泛应用于医药、农药、材料等领域。另一方面,季碳中心结构是许多天然产物和药物分子中的常见结构。三氟甲基和季碳中心相结合,即形成三氟甲基季碳中心(TFQC)。这是一种特殊的结构,特征为三氟甲基直接连接在四取代的碳原子上,使分子具有强的刚性和独特的电性。
目前已有的向分子内引入三氟甲基的方法,大多发生在sp2碳上,而合成C(sp3)-CF3键的方法相对较少,构建含三氟甲基季碳中心(TFQC)的方法更是有限。构筑季碳中心要克服较大的位阻,α-三氟甲基碳负离子的脱氟反应给三氟甲基季碳中心的构筑带来更大的挑战。由于α-三氟甲基碳负离子极易发生β-脱氟副反应,该类反应需要非常活泼的亲电试剂,例如活泼卤代物、π-烯丙基钯物种等,这就限制了反应的适用范围。
发明内容
本发明所要解决的技术问题是为了克服现有技术中三氟甲基季碳中心化合物制备困难、反应收率低的缺陷,提供了一种三氟甲基季碳中心化合物及其制备方法和应用。本发明通过从α-三氟甲基卤代物出发,采用引发手段,生成α-三氟甲基自由基,之后发生自由基加成反应构建含三氟甲基的季碳中心化合物。本发明的制备方法简单、反应收率高,得到的三氟甲基季碳中心化合物有较强的生物活性,对玉米锈病、黄瓜霜霉病、小麦白粉病和黄瓜炭疽病具有一定的防治效果。
本发明主要是通过以下技术方案解决上述技术难题的。
本发明提供了一种如式3或3’所示的三氟甲基季碳中心化合物,
其中X为卤素(例如F、Cl、Br或I);m为1、2、3、4或5;
R1为H、取代或未取代的C1~6烷基;
R2为H、取代或未取代的C1~6烷基;
R3为取代或未取代的C1~6烷氧基、取代或未取代的C6~10环烷氧基、芳香烃硫基、n为1、2、3、4或5。
其中,所述的R1较佳地为H、甲基或乙基,更佳地为H或甲基。
其中,所述的R2较佳地为H、甲基或乙基,更佳地为H或甲基。
其中,所述的C1~6烷氧基较佳地为甲氧基、乙氧基、丙氧基或丁氧基,更佳地为OEt、OiPr、OtBu或OnBu。
其中,所述的C6~10环烷氧基较佳地为或更佳地为
其中,所述的芳香烃硫基较佳地为SPh。
本发明中,所述的如式3或3’所示的三氟甲基季碳中心化合物进一步优选如下任一化合物:
本发明还提供了所述的如式3或3’所示的三氟甲基季碳中心化合物的制备方法,其包括下述步骤:
有机溶剂中,在催化剂的作用下,化合物1与化合物2或2’反应,即可得到化合物3或3’;
m、X、R1、R2、R3的定义均同上所述。
其中,所述的有机溶剂较佳地为二甲基甲酰胺、苯、甲苯、N-甲基吡咯烷酮和四氯化碳中的一种或多种,更佳地为二甲基甲酰胺。
其中,所述的催化剂较佳地为金属络合物催化剂,更佳地为Ru(bpy)3(PF6)2、fac-Ir(ppy)3、Ir(bpy)2(dtbbpy)(PF6)、Ir(dF(CF3)ppy)2(dtbbpy)(PF6),最佳地为Ir(dF(CF3)ppy)2(dtbbpy)(PF6)。本领域技术人员均清楚上述金属络合物催化剂为本领域常用的光引发催化剂。
其中,所述的反应较佳地为在可见光辐照下进行的反应,更佳地为在荧光辐照下进行的反应。
其中,所述的反应的温度较佳地为15~30℃。
其中,所述的化合物1与所述的化合物2或2’的摩尔比较佳地为1∶(1~10)。
其中,所述的反应的进程可通过本领域常规手段(如TLC或HPLC)进行监测,一般以化合物1消失时作为反应的终点,所述的反应的时间较佳地为1分钟~1小时,更佳地为10分钟~1小时。
其中,所述的反应结束后还可包括后处理过程。所述后处理过程优选包括如下步骤:倒入水和乙酸乙酯中分液,水相用乙酸乙酯萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,抽滤,柱层析即可。
本发明还提供了所述的如式3或3’所示的三氟甲基季碳中心化合物在制备治疗和/或预防植物疾病的药物中的应用;所述的植物疾病较佳地包括黄瓜霜霉病、小麦白粉病、黄瓜炭疽病、玉米锈病中的一种或多种。
本发明提供了一种如式5所示的三氟甲基季碳中心化合物,
其中X为卤素(例如F、Cl、Br或I);
R1为H、取代或未取代的C1~6烷基;
R2为H、取代或未取代的C1~6烷基;
R4为H、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的蒽基;
R5为H、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的蒽基;
R4与R5不同时为H。
其中,所述的R1较佳地为H、甲基或乙基,更佳地为H或甲基。
其中,所述的R2较佳地为H、甲基或乙基,更佳地为H或甲基。
其中,所述的取代或未取代的苯基较佳地为其中R6为H、C1~6烷基、C1~6烷氧基、C6~10环烷氧基、卤素(例如F、Cl、Br或I)、乙酰氧基或苯基;所述的C1~6烷基较佳地为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基,所述的C1~6烷氧基较佳地为甲氧基、乙氧基、OiPr、OtBu或OnBu,所述的C6~10环烷氧基较佳地为或
本发明中,所述的如式5所示的三氟甲基季碳中心化合物进一步优选如下任一化合物:
本发明还提供了所述的如式5所示的三氟甲基季碳中心化合物的制备方法,其包括下述步骤:
有机溶剂中,在催化剂的作用下,化合物1与化合物4反应,即可得到化合物5;
X、R1、R2、R4、R5的定义均同上所述。
其中,所述的有机溶剂较佳地为二甲基甲酰胺、苯、甲苯、N-甲基吡咯烷酮和四氯化碳中的一种或多种,更佳地为二甲基甲酰胺。
其中,所述的催化剂较佳地为金属络合物催化剂,更佳地为Ru(bpy)3(PF6)2、fac-Ir(ppy)3、Ir(ppy)2(dtbbpy)(PF6)、Ir(dF(CF3)ppy)2(dtbbpy)(PF6),最佳地为Ir(ppy)2(dtbbpy)(PF6)。本领域技术人员均清楚上述金属络合物催化剂为本领域常用的光引发催化剂。
其中,所述的反应较佳地为在可见光辐照下进行的反应,更佳地为在荧光辐照下进行的反应。
其中,所述的反应的温度较佳地为15~30℃。
其中,所述的化合物1与所述的化合物4的摩尔比较佳地为1∶(1~10)。
其中,所述的反应的进程可通过本领域常规手段(如TLC或HPLC)进行监测,一般以化合物1消失时作为反应的终点,所述的反应的时间较佳地为1分钟~20小时,更佳地为10小时~20小时。
其中,所述的反应结束后还可包括后处理过程。所述后处理过程优选包括如下步骤:倒入水和乙酸乙酯中分液,水相用乙酸乙酯萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,抽滤,柱层析即可。
本发明还提供了所述的如式5所示的三氟甲基季碳中心化合物在制备治疗和/或预防植物疾病的药物中的应用;所述的植物疾病较佳地包括黄瓜霜霉病、小麦白粉病、黄瓜炭疽病、玉米锈病中的一种或多种。
本发明提供了一种如式7所示的三氟甲基季碳中心化合物,
其中X为卤素(例如F、Cl、Br或I);
R1为H、取代或未取代的C1~6烷基;
R2为H、取代或未取代的C1~6烷基;
R7为C1~10烷基、 n为1、2、3、4或5,R8为H、C1~6烷基、C1~6烷氧基、C6~10环烷氧基、卤素(例如F、Cl、Br或I)、三氟甲基或氰基;R9为H、C1~6烷基、C1~6烷氧基、C6~10环烷氧基、卤素(例如F、Cl、Br或I)、三氟甲基或氰基。
其中,所述的R1较佳地为H、甲基或乙基,更佳地为H或甲基。
其中,所述的R2较佳地为H、甲基或乙基,更佳地为H或甲基。
其中,所述的C1~10烷基较佳地为C6~10烷基,更佳地为-C8H17。
其中,所述的C1~6烷基较佳地为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基,所述的C1~6烷氧基较佳地为甲氧基、乙氧基、OiPr、OtBu或OnBu,所述的C6~10环烷氧基较佳地为或
本发明中,所述的如式7所示的三氟甲基季碳中心化合物进一步优选如下任一化合物:
本发明还提供了所述的如式7所示的三氟甲基季碳中心化合物的制备方法,其包括下述步骤:
有机溶剂中,在催化剂的作用下,化合物1与化合物6反应,即可得到化合物7;
X、R1、R2、R7的定义均同上所述。
其中,所述的有机溶剂较佳地为二甲基甲酰胺、苯、甲苯、N-甲基吡咯烷酮和四氯化碳中的一种或多种,更佳地为二甲基甲酰胺。
其中,所述的催化剂较佳地为金属络合物催化剂,更佳地为Ru(bpy)3(PF6)2、[Ir(bpy)3Cl]2、Ir(bpy)2(dtbbpy)(PF6)、Ir(ppy)2(dtbbpy)(PF6)、Ir(dF(CF3)ppy)2(dtbbpy)(PF6)、fac-Ir(ppy)3,最佳地为fac-Ir(ppy)3。本领域技术人员均清楚上述金属络合物催化剂为本领域常用的光引发催化剂。
其中,所述的反应较佳地为在可见光辐照下进行的反应,更佳地为在荧光辐照下进行的反应。
其中,所述的反应的温度较佳地为15~30℃。
其中,所述的化合物1与所述的化合物6的摩尔比较佳地为1∶(1~10)。
其中,所述的反应的进程可通过本领域常规手段(如TLC或HPLC)进行监测,一般以化合物1消失时作为反应的终点,所述的反应的时间较佳地为1分钟~20小时,更佳地为10小时~20小时。
其中,所述的反应结束后还可包括后处理过程。所述后处理过程优选包括如下步骤:倒入水和乙酸乙酯中分液,水相用乙酸乙酯萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,抽滤,柱层析即可。
本发明还提供了所述的如式7所示的三氟甲基季碳中心化合物在制备治疗和/或预防植物疾病的药物中的应用;所述的植物疾病较佳地包括黄瓜霜霉病、小麦白粉病、黄瓜炭疽病、玉米锈病中的一种或多种。
本发明提供了一种如式9所示的三氟甲基季碳中心化合物,
其中X为卤素(例如F、Cl、Br或I);
R1为H、取代或未取代的C1~6烷基、苯基、甲苯基或苯甲基;
R2为H、取代或未取代的C1~6烷基、苯基、甲苯基或苯甲基;
R10为C6~10烯基、R11为H、C1~6烷基、C1~6烷氧基、C6~10环烷氧基、苯基、卤素(例如F、Cl、Br或I)、氰基或三氟甲基。
其中,所述的R1较佳地为H、甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、苯基、甲苯基或苯甲基。
其中,所述的R2较佳地为H、甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、苯基、甲苯基或苯甲基。
其中,所述的C6~10烯基较佳地为
其中,所述的C1~6烷基较佳地为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基,所述的C1~6烷氧基较佳地为甲氧基、乙氧基、OiPr、OtBu或OnBu,所述的C6~10环烷氧基较佳地为或
本发明中,所述的如式9所示的三氟甲基季碳中心化合物进一步优选如下任一化合物:
本发明还提供了所述的如式9所示的三氟甲基季碳中心化合物的制备方法,其包括下述步骤:
有机溶剂中,在催化剂的作用下,化合物1与化合物8反应,即可得到化合物9;
X、R1、R2、R10的定义均同上所述。
其中,所述的有机溶剂较佳地为二甲基甲酰胺、二甲基乙酰胺、二甲基亚砜、CH3CN、CH3NO2、N-甲基吡咯烷酮和四氯化碳中的一种或多种,更佳地为二甲基甲酰胺。
其中,所述的催化剂较佳地为金属络合物催化剂,更佳地为Ru(bpy)3Cl2、Ru(bpy)3(PF6)2、[Ir(bpy)3Cl]2、Ir(bpy)2(dtbbpy)(PF6)、Ir(ppy)2(dtbbpy)(PF6)、Ir(dF(CF3)ppy)2(dtbbpy)(PF6)、fac-Ir(ppy)3,最佳地为fac-Ir(ppy)3。本领域技术人员均清楚上述金属络合物催化剂为本领域常用的光引发催化剂。
其中,所述的反应较佳地为在可见光辐照下进行的反应,更佳地为在荧光辐照下进行的反应。
其中,所述的反应的温度较佳地为15~30℃。
其中,所述的化合物1与所述的化合物8的摩尔比较佳地为1∶(1~10)。
其中,所述的反应的进程可通过本领域常规手段(如TLC或HPLC)进行监测,一般以化合物1消失时作为反应的终点,所述的反应的时间较佳地为1分钟~20小时,更佳地为10小时~20小时。
其中,所述的反应结束后还可包括后处理过程。所述后处理过程优选包括如下步骤:倒入水和乙酸乙酯中分液,水相用乙酸乙酯萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,抽滤,柱层析即可。
本发明还提供了所述的如式9所示的三氟甲基季碳中心化合物在制备治疗和/或预防植物疾病的药物中的应用;所述的植物疾病较佳地包括黄瓜霜霉病、小麦白粉病、黄瓜炭疽病、玉米锈病中的一种或多种。
在符合本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于:本发明的制备方法简单、反应收率高,得到的三氟甲基季碳中心化合物有较强的生物活性,对玉米锈病、黄瓜霜霉病、小麦白粉病和黄瓜炭疽病具有一定的防治效果。
具体实施方式
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
本发明中,室温是指15~30℃。
在干燥的10mL Schlenk管中加入Ir[dF(CF3)ppy]2(dtbbpy)(PF6)(11.23mg,2mmol%),严格抽换氮气三次,在氮气条件下加入DMF(1mL),底物1(0.5mmol)和富电子烯烃化合物2(1.0mmol),置于24瓦荧光灯照射下室温搅拌反应1小时。体系倒入水(20mL)和乙酸乙酯(20mL)中分液,水相用乙酸乙酯萃取三次(5mL×3),合并有机相,饱和食盐水洗三次(5mL×3),无水硫酸钠干燥,抽滤,硅胶柱层析得到产物。
实施例1
制备化合物3a:
浅黄色液体;分离产率85%;IR(neat)v/cm-1:2979,1759,1722,1435,1378,1280,1195,1096,991,924,799;1H NMR(400MHz,CDCl3)δ1.19-1.27(m,3H),2.29(dd,J=14.4,4.4Hz,0.53H),2.64(t,J=4.8Hz,1H),2.86(dd,J=14.4,7.6Hz,0.47H),3.42-3.68(m,5H),3.82(m,3H),3.86-3.94(m,1H),5.08(dd,J=4.8,2.8Hz,0.47H),5.20(dd,J=6.4,3.6Hz,0.53H);19F NMR(376MHz,CDCl3)δ-70.7(s,1.4F),-70.2(s,1.6F);13C NMR(100MHz,CDCl3)δ15.2,15.3,27.8,28.3,32.9,33.4,43.0,43.5,53.7,53.8,59.3(q,JCF=28Hz),63.3,63.6,87.0,123.0(q,JCF=279Hz),123.3(q,JCF=277Hz),163.7,164.6,165.4,165.6;MS(ESI)m/z(%):362[M+1]+;HRMS(ESI)calcd.for C11H15BrF3NNaO4[M+Na]+:384.0029;found:384.0046.
实施例2
制备化合物3b:
浅黄色液体;分离产率83%;IR(neat)v/cm-1:2974,2928,2856,1760,1723,1435,1327,1279,1143,1089,1030,956,866,801,711;1H NMR(400MHz,CDCl3)δ1.17-1.29(m,6H),2.27(dd,J=14.4,4.4Hz,0.53H),2.59-2.70(m,1H),2.89(dd,J=14.4,6.0Hz,0.47H),3.44-3.66(m,3H),3.74-3.93(m,5H),5.15(dd,J=5.2,2.4Hz,0.47H),5.26(dd,J=6.4,4.4Hz,0.53H);19F NMR(376MHz,CDCl3)δ-70.3(s,1.4F),-69.8(s,1.6F);13C NMR(100MHz,CDCl3)δ22.1,22.4,23.0,23.3,28.2,28.6,29.6,34.5,35.2,42.8,43.3,53.8,59.2(q,JCF=17Hz),70.8,72.0,85.7,86.1,123.0(q,JCF=284Hz),123.4(q,JCF=274Hz),163.5,164.6,165.4,165.7;MS(ESI)m/z(%):378[M+1]+;HRMS(ESI)calcd.for C12H17BrF3NNaO4[M+Na]+:398.0185;found:398.0194.
实施例3
制备化合物3c:
乳白色固体;m.p.55.6-57.9℃;分离产率84%;IR(KBr)v/cm-1:2976,2925,2853,1761,1721,1436,1396,1368,1322,1279,1192,1086,1027,897,745;1H NMR(400MHz,CDCl3)δ1.26-1.28(m,9H),2.23(dd,J=14.4,4.4Hz,0.57H),2.55(d,J=12.0Hz,0.43H),2.70(dd,J=14.0,6.0Hz,0.43H),2.85(dd,J=14.0,6.4Hz,0.57H),3.42-3.63(m,3H),3.71-3.78(m,1H),3.82(s,3H),5.25-5.35(m,1H);19F NMR(376MHz,CDCl3)δ-69.9(s,1.3F),-69.5(s,1.7F);13C NMR(100MHz,CDCl3)δ28.4,28.6,36.6,36.9,42.3,42.8,53.7,59.5(q,JCF=28Hz),74.8,75.0,81.3,81.4,123.0(q,JCF=280Hz),163.4,164.4,166.5;MS(ESI)m/z(%):390[M+1]+;HRMS(ESI)calcd.for C13H19BrF3NNaO4[M+Na]+:412.0342;found:412.0345.
实施例4
制备化合物3d:
浅黄色液体;分离产率80%;IR(neat)v/cm-1:2960,2931,2874,1762,1723,1453,1435,1365,1326,1278,1197,1097,1074;isomer a:1H NMR(400MHz,CDCl3)δ0.94(t,J=6.8Hz,3H),1.35-1.44(m,2H),1.56-1.63(m,2H),2.30(dd,J=14.0,4.0Hz,1H),2.86(dd,J=14.4,6.4Hz,1H),3.44-3.68(m,5H),3.84(s,3H),3.87-3.91(m,1H),5.21(dd,J=6.0,3.6Hz,1H);19F NMR(376MHz,CDCl3)δ-69.8(s);13C NMR(100MHz,CDCl3)δ13.7,19.2,27.8,31.7,33.2,42.0,53.7,59.3(q,JCF=28Hz),67.8,87.1,123.6(q,JCF=280Hz),163.7,165.5;isomer b:1H NMR(400MHz,CDCl3)δ:0.93(t,J=6.8Hz,3H),1.32-1.42(m,2H),1.53-1.60(m,2H),2.60-2.69(m,2H),3.47-3.50(m,3H),3.56-3.61(m,2H);3.84(s,3H),3.87-3.94(m,1H),5.08-5.10(m,1H);19F NMR(376MHz,CDCl3)δ:-70.3(s);13C NMR(100MHz,CDCl3)δ:13.7,18.8,28.3,31.6,32.7,43.5,53.8,59.0(q,JCF=27Hz),67.5,87.1,123.3(q,JCF=280Hz),164.7,165.3;MS(ESI)m/z(%):390,392[M+1]+;HRMS(ESI)calcd.forC13H20BrF3NO4[M+1]+:390.0522;found:390.0522.
实施例5
制备化合物3e:
浅黄色液体;分离产率71%;IR(neat)v/cm-1:2935,2858,1759,1720,1452,1436,1364,1436,1364,1325,1279,1195,1091,1026,980,925,713;1H NMR(400MHz,CDCl3)δ1.20-1.45(m,5H),1.51-1.58(m,1H),1.68-1.95(m,4H),2.27(dd,J=14.0,4.4Hz,0.42H),2.60-2.69(m,1H),2.88(dd,J=14.4,6.4Hz,0.58H),3.41-3.54(m,2H),3.56-3.66(m,2H),3.83(s,3H),3.85-3.91(m,1H),5.18(dd,J=4.2,2.8Hz,0.42H),5.29(dd,J=6.0,4.2Hz,0.58H);19F NMR(376MHz,CDCl3)δ-70.3(s,1.3F),-69.8(s,1.7F);13C NMR(100MHz,CDCl3)δ23.6,23.8,25.2,27.9,28.3,31.9,32.2,33.0,33.3,34.6,35.2,42.8,43.2,53.6,58.8-59.9(m),76.3,77.5,85.5,85.9,122.9(q,JCF=279Hz),123.3(q,JCF=280Hz),163.4,164.5,165.3,165.5;MS(ESI)m/z(%):418[M+1]+;HRMS(ESI)calcd.for C15H21BrF3NO4Na[M+Na]+:438.0498;found:438.0517.
实施例6
制备化合物3f:
浅黄色液体;分离产率52%;IR(neat)v/cm-1:3058,2957,2860,1761,1717,1583,1474,1438,1413,1298,1252,1193,1093,1060,876,805,751,694,605;1H NMR(400MHz,CDCl3)δ:2.40(dd,J=14.4,7.2Hz,0.57H),2.79(dd,J=14.8,4.8Hz,0.43H),2.91-2.98(m,1H),3.41-3.46(m,1H),3.52-3.60(m,1H),3.71(s,1.39H),3.82(s,1.71H),3.91-3.97(m,1H),4.12-4.22(m,1H),5.10-5.17(m,1H),7.34-7.41(m,4H),7.43-7.46(m,1H);19F NMR(376MHz,CDCl3)δ-70.3(s,1.3F),-70.1(s,1.7F);13C NMR(100MHz,CDCl3)δ27.2,27.5,32.5,33.2,42.9,43.3,53.7,59.3(m),64.5,65.6,123.4(q,JCF=281Hz),122.8(q,JCF=280Hz),129.3,129.6,134.7,134.9,164.1,164.3,165.1;MS(ESI)m/z(%):428[M+1]+;HRMS(ESI)calcd.for C15H15BrF3NO3SNa[M+Na]+:447.9800;found:447.9814.
实施例7
制备化合物3g:(该实施例中,反应物为)
浅黄色液体;分离产率73%;IR(neat)v/cm-1:2960,2892,1754,1716,1442,1372,1301,1251,1197,1087,1032,978,935,863;1H NMR(400MHz,CDCl3)δ1.67-1.71(m,1H),2.04-2.27(m,2H),3.27-3.36(m,1H),3.49-3.55(m,1H),3.57-3.66(m,1H),3.68-3.79(m,2H),3.84(s,1.70H),3.85(s,1.30H),3.86-4.02(m,1H),5.64-5.66(m,1H);19F NMR(376MHz,CDCl3)δ-70.1(s,1.3F),-64.0(s,1.7F);13C NMR(100MHz,CDCl3)δ:27.1,27.6,41.0,42.7,43.4,44.0,53.2,53.9,62.8(q,JCF=21Hz),66.5,66.8,91.1,91.6,123.0(q,JCF=281Hz),163.8,165.9;MS(ESI)m/z(%):360,362[M+1]+;HRMS(ESI)calcd.forC11H13BrF3NNaO4[M+Na]+:381.9872;found:381.9889.
实施例8
制备化合物3h:
白色固体;m.p.114.7-118.9℃;分离产率66%;IR(KBr)v/cm-1:2959,1762,1699,1415,1261,1195,1163,1080,1017,879,711,619;isomer a:1H NMR(400MHz,CDCl3)δ2.02-2.15(m,2H),2.32(dd,J=14.4,6.4Hz,1H),2.49(t,J=8.0Hz,2H),2.79(dd.J=14.8,8.0Hz,1H),3.06-3.19(m,2H),3.36-3.42(m,1H),3.46-3.55(m,2H),3.83(s,3H),3.96-4.03(m,1H),6.07(t,J=7.6Hz,1H);19F NMR(376MHz,CDCl3)δ-70.0(s);13C NMR(100MHz,CDCl3)δ17.9,26.4,28.0,31.2,40.9,42.3,53.8,59.3(q,JCF=28Hz),61.9,123.2(q,JCF=287Hz),163.9,165.0,176.3;mixture:1H NMR(400MHz,CDCl3)δ1.98-2.13(m,2H),2.27-2.34(m,0.39H),2.42-2.50(m,2H),2.53-2.59(m,0.61H),2.72-2.81(m,1H),3.04-3.18(m,2H),3.33-3.40(m,1H),3.46-3.47(m,2H),3.78-3.85(m,3H),3.92-4.03(m,1H),5.95-6.07(m,1H);19F NMR(376MHz,CDCl3)δ-70.3(s,2.0F),-70.0(s,1.0F);13C NMR(100MHz,CDCl3)δ17.7,26.4,27.8,28.1,31.0,31.1,40.8,41.1,42.1,53.7,53.8,59.5(q,JCF=28Hz),61.8,61.9,123.2(q,JCF=281Hz),163.8,163.9,164.7,165.5,176.1,176.2;MS(ESI)m/z(%):401,403[M+1]+;HRMS(ESI)calcd.for C13H17BrF3N2O4[M+1]+:401.0318;found:401.0317.Anal.calcd for C13H16BrF3N2O4:C,38.92;H,4.02;N,6.98;Found:C,39.20;H,4.07;N,6.99.
实施例9
制备化合物3i:
白色固体;m.p.98.5-100.3℃;分离产率51%;IR(KBr)v/cm-1:2933,2859,1762,1720,1655,1436,1415,1352,1307,1278,1259,1193,1095,1045,973;1H NMR(400MHz,CDCl3)δ1.41-1.68(m,3H),1.75-1.92(m,3H),2.11-2.20(m,0.50H),2.44-2.51(m,0.50H),2.55-2.94(m,2H),2.73-2.84(m,1H),3.01-3.10(m,1H),3.12-3.35(m,2H),3.39-3.55(m,2H),3.81-3.89(m,3H),3.94-4.04(m,1H),6.43-6.57(m,1H);19F NMR(376MHz,CDCl3)δ-70.1(1.5F),-69.9(s,1.5F);13C NMR(100MHz,CDCl3)δ:23.2,26.2,28.9,29.2,29.3,29.6,37.5,41.3,41.8,42.2,53.7,53.9,58.8-60.2(m),63.7,64.3,123.1(q,JCF=279Hz),123.3(q,JCF=281Hz),164.1,164.2,164.8,165.9,177.3;MS(ESI)m/z(%):429[M+1]+;HRMS(ESI)calcd.for C15H20BrF3N2O4Na[M+Na]+:451.0451;found:451.0437.Anal.calcd forC15H20BrF3N2O4:C,41.97;H,4.70;N,6.53;Found:C,42.28;H,4.74;N,6.48.
实施例10
制备化合物3j:
白色固体;m.p.57.4-59.2℃;分离产率88%;IR(KBr)v/cm-1:3053,2957,2919,2849,1763,1722,1625,1598,1485,1451,1410,1325,1267,1195,1072,751,724;1H NMR(400MHz,CDCl3)δ2.85-2.96(m,1H),2.99-3.10(m,1H),3.18-3.36(m,2H),3.59-3.68(m,1H),3.96-3.98(m,3H),4.00-4.10(m,1H),6.70-6.80(m,1H),7.25-7.33(m,2H),7.42(dd,J=16.0,8.0Hz,1H),7.48-7.56(m,3H),8.10(t,J=8.0Hz,2H);19F NMR(376MHz,CDCl3)δ-69.6(s,1.4F),-68.8(s,1.6F);13C NMR(100MHz,CDCl3)δ27.6,27.9,30.8,31.1,42.3,42.5,54.0,54.2,60.3(m),67.0,67.4,108.4,110.7,111.3,120.7,120.77,120.82,120.9,121.0,123.3(q,JCF=280Hz),123.5,123.7(q,JCF=281Hz),124.7,124.9,126.50,126.56,126.59,126.7,136.7,136.9,140.0,163.8,164.0,165.0,165.5;MS(ESI)m/z(%):485[M+1]+;HRMS(ESI)calcd.for C21H18BrF3N2O3Na[M+Na]+:505.0345;found:505.0321.
实施例11
制备化合物3k:
无色液体,分离产率84%;IR(neat)v/cm-1:2980,2881,1759,1716,1445,1401,1304,1194,1089,944,760,677;1H NMR(400MHz,CDCl3)δ1.18(t,J=6.8Hz,1.41H),1.24(t,J=7.2Hz,1.59H),1.53(s,3H),1.59(s,3H),2.33(d,J=14.8Hz,0.53H),2.41(dd,J=13.6,4.8Hz,0.47H),2.71(d,J=13.6Hz,0.47H),2.83(dd,J=14.8,6.4Hz,0.53H),3.33(dd,J=10.0,5.6Hz,1H),3.36-3.52(m,2H),3.82-3.83(m,3H),4.48(d,J=10.4Hz,0.47H),4.54(d,J=10.4Hz,0.53H),4.93(d,J=4.4Hz,0.53H),5.05(d,J=6.4Hz,0.47H);19F NMR(376MHz,CDCl3)δ-70.2(s,1.33F),-69.5(s,1.67F);13C NMR(100MHz,CDCl3)δ15.1,31.5,40.2,40.9,53.6,53.8,57.4,58.0,59.2-60.0(m),61.8,62.1,86.0,86.8,123.0(q,JCF=280Hz),123.3(q,JCF=280Hz),164.6,165.6,165.8,165.9;MS(ESI)m/z(%):390[M+1]+;HRMS(ESI)calcd.for C13H20BrF3NO4[M+1]+:390.0522;found:390.0522.
在干燥的10mL Schlenk管中加入Ir(ppy)2(dtbbpy)(PF6)(6.5mg,2mmol%),严格抽换氮气三次,在氮气条件下加入DMF(1mL),底物1(0.5mmol)和芳基烯烃4(1.0mmol),置于24瓦荧光灯照射下室温搅拌反应过夜。体系倒入水(20mL)和乙酸乙酯(20mL)中分液,水相用乙酸乙酯萃取三次(5mL×3),合并有机相,饱和食盐水洗三次(5mL×3),无水硫酸钠干燥,抽滤,硅胶柱层析得到产物。
实施例12
制备化合物5a:
浅黄色液体;分离产率68%;IR(neat)v/cm-1:3024,2958,2924,1759,1713,1615,1515,1434,1279,1193,1097,1063,1021,883,822,733,506;1H NMR(400MHz,CDCl3)δ2.31-2.36(m,3.42H),2.61(dd,J=14.4,7.2Hz,0.58H),2.86-2.96(m,1H),2.99-3.07(m,1H),3.20-3.27(m,1H),3.40-3.52(m,1H),3.84-3.85(m,3H),3.94-4.00(m,1H),4.83-4.91(m,1H),7.12-7.24(m,4H);19F NMR(376MHz,CDCl3)δ-70.1(s,1.5F),-70.0(s,1.5F);13C NMR(100MHz,CDCl3)δ:21.0,27.3,27.4,35.4,35.8,43.0,43.2,53.5,53.6,59.6,59.8(q,JCF=27Hz),60.1,123.3(q,JCF=280Hz),123.8(q,JCF=282Hz),127.0,127.1,129.96,130.02,134.6,135.2,139.0,139.1,165.2,165.3,165.5,166.1;MS(ESI)m/z(%):410[M+1]+;HRMS(ESI)calcd.for C16H18BrF3NO3[M+1]+:408.0417;found:408.0414.
实施例13
制备化合物5b:
白色固体;m.p.49.7-51.6℃;分离产率66%;IR(KBr)v/cm-1:2958,1759,1714,1496,1458,1435,1300,1269,1245,1193,1058,764,702;1H NMR(400MHz,CDCl3)δ2.37(dd,J=14.0,8.8Hz,0.50H),2.66(dd,J=15.2,7.6Hz,0.50H),2.92-3.10(m,2H),3.26-3.32(m,1H),3.46-3.57(m,1H),3.88(s,1.50H),3.91(s,1.50H),4.01-4.08(m,1H),4.91-4.99(m,1H),7.29-7.33(m,2H),7.39-7.47(m,3H);19F NMR(376MHz,CDCl3)δ-70.1(s,1.5F),-70.0(s,1.5F);13C NMR(100MHz,CDCl3)δ27.4,27.5,35.5,35.9,43.2,43.4,53.7,53.8,59.8(q,JCF=25Hz),60.1.60.5,123.4(q,JCF=280Hz),123.9(q,JCF=280Hz),127.20,127.22,129.2,129.3,129.4,129.5,137.9,138.5,165.3,165.4,165.5,166.1;MS(ESI)m/z(%):396[M+1]+;HRMS(ESI)calcd.for C15H16BrF3NO3[M+1]+:394.0260;found:394.0261.
实施例14
制备化合物5c:
浅黄色液体;分离产率56%;IR(neat)v/cm-1:2958,2840,1758,1713,1613,1587,1514,1434,1301,1250,1194,1177,1063,1033,835;1H NMR(400MHz,CDCl3)δ2.37(dd,J=14.4,8.8Hz,0.64H),2.65(dd,J=14.8,8.0Hz,0.36H),2.89-2.97(m,1H),2.99-3.10(m,1H),3.24-3.31(m,1H),3.44-3.55(m,1H),3.83(s,3H),3.89(s,1.09H),3.90(s,1.91H),3.96-4.03(m,1H),4.86-4.94(m,1H),6.95(d,J=8.4Hz,2H),7.20-7.28(m,2H);19F NMR(376MHz,CDCl3)δ-70.1(s,1.9F),-70.0(s,1.1F);13C NMR(100MHz,CDCl3)δ27.4,27.6,35.6,35.9,43.0,43.2,53.6,53.7,55.3,59.4,59.8(q,JCF=28Hz),60.0,114.7,114.8,123.4(q,JCF=279Hz),123.9(q,JCF=281Hz),128.6,129.4,130.1,160.1,160.2,165.2,165.3,165.6,166.2;MS(ESI)m/z(%):426[M+1]+;HRMS(ESI)calcd.for C16H18BrF3NO4[M+1]+:424.0366;found:424.0366.
实施例15
制备化合物5d:
浅黄色液体;分离产率65%;IR(neat)v/cm-1:2963,2906,2870,1759,1706,1512,1435,1413,1268,1188,1109,1061,1018,837,674;1H NMR(400MHz,CDCl3)δ1.33(s,9H),2.38(dd,J=14.0,5.2Hz,0.29H),2.65(dd,J=14.4,7.2Hz,0.71H),2.89-2.97(m,1H),3.03-3.10(m,1H),3.26-3.32(m,1H),3.46-3.57(m,1H),3.87(s,0.89H),3.89(s,2.11H),3.99-4.06(m,1H),4.87-4.96(m,1H),7.18-7.24(m,2H),7.42-7.44(d,J=8.4Hz,2H);19FNMR(376MHz,CDCl3)δ-70.1(s,2.2F),-70.0(s,0.8F);13C NMR(100MHz,CDCl3)δ20.8,27.2,27.3,35.3,35.7,43.1,43.2,53.5,53.6,59.3,59.6(q,JCF=52Hz),59.7,122.5,122.6,123.2(q,JCF=279Hz),123.7(q,JCF=281Hz),128.2,135.2,135.9,150.9,151.0,165.1,165.2,165.9,169.0;MS(ESI)m/z(%):452[M+1]+;HRMS(ESI)calcd.for C19H24BrF3NO3[M+1]+:450.0886;found:450.0883.
实施例16
制备化合物5e:
浅黄色液体;分离产率72%;IR(neat)v/cm-1:2959,1758,1713,1607,1508,1434,1370,1300,1281,1195,1167,1062,1016,912,851,659;1H NMR(400MHz,CDCl3)δ2.32-2.38(m,3.53H),2.64(dd,J=14.4,6.4Hz,0.47H),2.93-3.02(m,1H),3.04-3.10(m,1H),3.27-3.34(m,1H),3.47-3.58(m,1H),3.86(s,1.41H),3.89(s,1.59H),4.02-4.09(m,1H),4.95-5.03(m,1H),7.16-7.18(m,2H),7.30-7.37(m,2H);19F NMR(376MHz,CDCl3)δ-70.1(s,1.6F),-70.0(s,1.4F);13C NMR(100MHz,CDCl3)δ27.4,27.5,31.2,34.7,36.0,43.2,43.4,53.6,53.7,59.8,60.1(q,JCF=20Hz),123.4(q,JCF=279Hz),126.3,126.4,126.9,134.8,135.4,152.3,152.5,165.3,165.5,165.6,166.2;MS(ESI)m/z(%):454[M+1]+;HRMS(ESI)calcd.for C17H18BrF3NO5[M+1]+:452.0315;found:452.0310.
实施例17
制备化合物5f:
白色固体;m.p.100.3-101.5℃;分离产率59%;IR(KBr)v/cm-1:3030,2957,1758,1713,1487,1450,1435,1413,1299,1270,1189,1060,1008,842,765,698,503;1H NMR(400MHz,CDCl3)δ2.43(dd,J=14.0,8.4Hz,0.22H),2.71(dd,J=14.4,7.2Hz,0.78H),2.99-3.05(m,1H),3.09-3.16(m,1H),3.30-3.35(m,1H),3.50-3.55(m,1H),3.90(s,2.43H),3.92(s,0.57H),4.05-4.12(m,1H),4.97-5.05(m,1H),7.34-7.41(m,3H),7.47(t,J=7.6Hz,2H),7.60(d,J=7.2Hz,2H),7.66(d,J=8.4Hz,2H);19F NMR(376MHz,CDCl3)δ-70.0(s,0.7F),-69.9(s,2.3F);13C NMR(100MHz,CDCl3)δ27.4,27.5,35.5,35.9,43.3,43.5,53.7,59.9(q,JCF=14.1Hz),60.3,123.8(q,JCF=281Hz),127.0,127.7,127.8,128.1,128.2,128.9,136.8,137.4,140.0,142.2,142.3,165.3,166.1;MS(ESI)m/z(%):472[M+1]+;HRMS(ESI)calcd.for C21H19BrF3NNaO3[M+Na]+:492.0393;found:492.0381.
实施例18
制备化合物5g:
白色固体;m.p.101.2-104.4℃;分离产率42%;IR(KBr)v/cm-1:2959,2924,2853,1758,1714,1606,1512,1436,1270,1228,1188,1059,841,549;isomer a(for X-raysingle crystal analysis):1H NMR(400MHz,CDCl3)δ2.61(dd,J=14.8,7.6Hz,1H),2.94-3.04(m,2H),3.24-3.30(m,1H),3.45-3.51(m,1H),3.87(s,3H),3.99-4.05(m,1H),4.93(t,J=7.2Hz,1H),7.11(t,J=8.4Hz,2H),7.28-7.31(m,2H);19F NMR(376MHz,CDCl3)δ-111.9to-111.8(m,1F),-69.7(s,3F);13C NMR(100MHz,CDCl3)δ27.3,35.6,43.4,53.8,60.0,60.1(q,JCF=22Hz),116.4,116.6,123.8(q,JCF=281Hz),129.0,129.1,134.4,161.8,164.2,165.3;mixture:1H NMR(400MHz,CDCl3)δ2.31(dd,J=14.0,8.4Hz,0.48H),2.60(dd,J=14.8,7.2Hz,0.52H),2.90-3.04(m,2H),3.23-3.30(m,1H),3.44-3.57(m,1H),3.85(s,1.56H),3.87(s,1.44H),3.97-4.05(m,1H),4.90-4.98(m,1H),7.08-7.12(m,2H),7.23-7.31(m,2H);19F NMR(376MHz,CDCl3)δ-120.3--120.0(m,0.5F),-111.8--111.7(m,0.5F),-70.1(s,1.5F),-70.0(s,1.5F);13C NMR(100MHz,CDClx)δ27.3,27.4,35.5,35.9,43.2,43.3,53.6,53.7,59.4,59.8,59.8(q,JCF=53Hz),116.3,116.4,116.5,116.6,123.2(q,JCF=279Hz),123.7(q,JCF=281Hz),129.0,129.1,133.65,133.68,134.29,134.32,164.1,164.2,165.2,165.3,165.4,166.0;MS(ESI)m/z(%):414[M+1]+;HRMS(ESI)calcd.for C15H14BrF4NO3Na[M+Na]+:433.9985;found:433.9991.
实施例19
制备化合物5h:
浅黄色液体;分离产率53%;IR(neat)v/cm-1:3030,2958,2925,2852,1755,1598,1493,1435,1413,1274,1092,1073,1021,883,833,785,759,508;1H NMR(400MHz,CDCl3)δ:2.32(dd,J=14.0,8.4Hz,0.48H),2.61(dd,J=14.4,6.8Hz,0.52H),2.93-3.06(m,2H),3.27-3.33(m,1H),3.47-3.59(m,1H),3.88(s,1.56H),3.90(s,1.44H),4.02-4.10(m,1H),4.92-5.01(m,1H),7.22(d,J=8.4Hz,1H),7.28(s,1H),7.40-7.43(m,2H);19F NMR(376MHz,CDCl3)δ-70.1(s,1.4F),-70.0(s,1.6F);13C NMR(100MHz,CDCl3)δ27.4,27.6,35.4,35.9,43.3,43.4,53.8,53.9,59.6,60.0(q,JCF=25Hz),60.0,123.2(q,JCF=276Hz),123.7(q,JCF=289Hz),128.6,129.7,129.8,135.1,135.3,136.5,137.1,165.3,163.4,166.1;MS(ESI)m/z(%):430[M+1]+;HRMS(ESI)calcd.for C15H15BrClF3NO3[M+1]+:427.9870;found:427.9866.
实施例20
制备化合物5i:
乳白色固体;m.p.82.4-85.1℃;分离产率33%;IR(KBr)v/cm-1:3050,2957,2925,1760,1714,1512,1434,1300,1267,1195,1161,1064,797,779;1H NMR(400MHz,CDCl3)δ2.36(dd,J=14.4,7.6Hz,1H),2.93-3.05(m,1H),3.16-3.26(m,1H),3.30-3.35(m,1H),3.58-3.64(m,1H),3.96-3.97(m,3H),4.13-4.28(m,1H),5.95(t,J=7.6Hz,1H),7.33(d,J=7.6Hz,1H),7.44-7.63(m,3H),7.87-7.96(m,2H),8.05(d,J=8.4Hz,1H);19F NMR(376MHz,CDCl3)δ-69.9(s,2.1F),-69.3(s,0.9F);13C NMR(100MHz,CDCl3)δ:27.4,27.9,33.5,35.8,43.2,43.9,53.8,54.9,60.0(q,JCF=28Hz),62.9,121.4,123.3(q,JCF=280Hz),122.4,123.1,125.2,125.8,126.3,126.4,127.2,127.3,129.2,129.3,129.9,130.2,130.4,130.8,130.9,134.0,134.5,165.3,165.5,165.8,166.0;MS(ESI)m/z(%):446[M+1]+;HRMS(ESI)calcd.for C19H17BrF3NO3Na[M+Na]+:466.0236;found:466.0250.
实施例21
制备化合物5j:
乳白色固体;m.p.98.9-103.4℃;分离产率46%;IR(KBr)v/cm-1:3061,2955,2864,1757,1716,1494,1448,1397,1318,1279,1193,1168,1055,758,703;1H NMR(400MHz,CDCl3)δ2.34-2.41(m,1H),2.86-2.93(m,1H),3.26-3.38(m,3H),3.48(s,3H),3.89-3.97(m,1H),7.15-7.17(m,2H),7.21-7.27(m,3H),7.32-7.41(m,5H);19F NMR(376MHz,CDCl3)δ-69.7(s);13C NMR(100MHz,CDCl3)δ25.9,43.1,45.0,53.4,59.4(q,JCF=27Hz),70.2,123.5(q,JCF=280Hz),127.6,128.2,128.3,128.5,128.9,129.0,140.8,140.4,164.9,165.1;MS(ESI)m/z(%):472[M+1]+;HRMS(ESI)calcd.for C21H19BrF3NO3Na[M+Na]+:492.0393;found:492.0375.
在干燥的10mL Schlenk管中加入fac-Ir(ppy)3(6.5mg,2mol%),严格抽换氮气三次,在氮气条件下加入DMF(1mL),底物1(0.5mmol)和普通烯烃6(1.0mmol),置于24瓦荧光灯照射下室温搅拌反应过夜。体系倒入水(20mL)和乙酸乙酯(20mL)中分液,水相用乙酸乙酯萃取三次(5mL×3),合并有机相,饱和食盐水洗三次(5mL×3),无水硫酸钠干燥,抽滤,硅胶柱层析得到产物。
实施例22
制备化合物7a:
无色液体;分离产率50%;IR(neat)v/cm-1:3409,2929,2857,1759,1713,1606,1594,1435,1378,1275,1195,1128,1062,1032,982,925,793,710,528;1H NMR(400MHz,CDCl3)δ0.88(t,J=8.0Hz,3H),1.19-1.41(m,12H),1.62-1.91(m,2H),2.04(dd,J=16.0,8.0Hz,1H),2.36(dd,J=14.0,8.0Hz,1H),2.61-2.68(m,1H),3.37-3.47(m,2H),3.51-3.59(m,1H),3.82-3.83(m,3H),4.00-4.05(m,1H);19F NMR(400MHz,CDCl3)δ-70.15(s,1.49F),-70.14(s,1.51F);13C NMR(400MHz,CDCl3)δ14.1,22.6,24.1,24.4,27.4,27.5,29.1,29.4,29.45,29.5,31.4,31.8,32.2,33.0,33.2,42.9.43.1,53.6,53.7,55.1,55.7,59.5-59.9(m),123.3(q,JCF=279Hz),123.8(q,JCF=281Hz),165.0,165.4,165.8,166.2;MS(ESI)m/z(%):430[M+1]+;HRMS(ESI)calcd.for C17H28BrF3NO3[M+1]+:430.1199;found:430.1197.
实施例23
制备化合物7b:
无色液体;分离产率50%;IR(neat)v/cm-1:3062,2956,2877,1757,1711,1629,1600,1511,1466,1435,1390,1258,1217,1184,1120,1062,1029,840,750,624;1H NMR(400MHz,CDCl3)δ1.81-2.04(m,1H),2.30-2.53(m,1H),2.61-2.66(m,1H),2.76-2.87(m,1H),3.45-3.51(m,3H),3.78-3.83(m,3H),4.07-4.24(m,4H),7.13-7.15(d,J=8.0Hz,2H),7.37(t,J=8.0Hz,1H),7.47(t,J=8.0Hz,1H),7.77(q,J=8.0Hz,3H);19F NMR(400MHz,CDCl3)δ-70.2(s,1.48F),-70.1(s,1.52F);13C NMR(400MHz,CDCl3)δ27.4,31.2,23,32.6,32.8,43.1,43.3,53.5,53.6,53.8,59.6(q,JCF=22Hz),63.6,106.6,118.4,123.3(q,JCF=226Hz),123.7(q,JCF=224Hz),123.9,126.5,126.7,127.6,129.1,129.6,134.3,156.1,165.0,165.4,165.6,166.1;MS(ESI)m/z(%):490[M+1]+;HRMS(ESI)calcd.forC21H22BrF3NO4[M+1]+:488.0679;found:488.0674.
实施例24
制备化合物7c:
无色液体;分离产率43%;IR(neat)v/cm-1:2955,2877,1758,1713,1601,1452,1435,1275,1190,1112,1070,1027,714;1H NMR(400MHz,CDCl3)δ1.39-1.52(m,3H),1.73-1.99(m,3H),2.03(dd,J=16.0,12.0Hz,0.54H),2.36(dd,J=12.0,4.0Hz,0.46H),2.61-2.68(m,1H),3.35-3.44(m,2H),3.46-3.57(m,1H),3.79-3.80(m,3H),3.81-4.06(m,2H),4.33(t,J=8.0Hz,2H),7.42(t,J=8.0Hz,2H),7.54(t,J=8.0Hz,1H),8.00(d,J=8.0Hz,2H);19F NMR(400MHz,CDCl3)δ-70.14(s,1.4F),-70.12(s,1.6F);13C NMR(400MHz,CDCl3)δ20.8,21.0,27.4,27.5,28.5,31.2,32.0,32.6,32.8,42.8,43.1,53.6,53.7,54.9,55.5,59.5(m),64.2,123.2(q,JCF=279Hz),123.7(q,JCF=280Hz),128.4,129.4,130.0,133.0,164.9,165.3,165.6,166.1,166.5;MS(ESI)m/z(%):494[M+1]+;HRMS(ESI)calcd.forC20H24BrF3NO5[M+1]+:494.0784;found:494.0780.
实施例25
制备化合物7d:
无色液体;分离产率47%;IR(neat)v/cm-1:2958,2903,2231,1758,1713,1435,1276,1190,1107,1020,862,768,692;1H NMR(400MHz,CDCl3)δ1.49-1.62(m,1H),1.73-1.86(m,2H),1.93-2.08(m,1.34H),2.39(dd,J=16.0,8.0Hz,0.66H),2.64-2.72(m,1H),3.35-3.57(m,3H),3.79(s,3H),3.89-4.09(m,2H),4.38(t,J=8.0Hz,2H),7.72(d,J=8.0Hz,2H),8.09(d,J=8.0Hz,2H);19F NMR(400MHz,CDCl3)δ-70.06(s,1.6F),-70.05(s,1.4F);13CNMR(400MHz,CDCl3)δ23.3,23.6,27.5,27.6,29.2,29.5,31.0,31.8,42.8,43.1,53.6,53.7,54.5,55.1,59.6(m),64.8,116.5,117.8,123.2(q,JCF=279Hz),123.6(q,JCF=281Hz),130.0,132.2,133.6,164.7,164.8,165.3,165.5,165.9;MS(ESI)m/z(%):507[M+1]+;HRMS(ESI)calcd.for C20H21BrF3N2O5[M+1]+:505.0591;found:505.0578.
实施例26
制备化合物7e:
无色液体;分离产率42%;IR(neat)v/cm-1:3041,2955,2882,1758,1712,1612,1434,1381,1275,1178,1108,1036,842,755,691;1H NMR(400MHz,CDCl3)δ1.37-1.47(m,2H),1.75-1.93(m,3H),2.00-2.04(m,1H),2.35(s,3H),2.59-2.66(m,1H),3.32-3.39(m,2H),3.42-3.55(m,1H),3.76-3.77(m,4H),3.78-4.03(m,1H),4.29(t,J=8.0Hz,3H),7.19(d,J=8.0Hz,2H),7.86(d,J=8.0Hz,2H);19F NMR(400MHz,CDCl3)δ-70.2(1.5F),-70.1(1.5F);13C NMR(400MHz,CDCl3)δ20.7,21.0,21.6,27.4,27.5,28.5,31.2,32.0,32.5,32.7,42.8,43.0,53.5,53.6,54.9,55.5,59.5(m),64.0,123.2(q,JCF=279Hz),123.7(q,JCF=281Hz),127.3,129.1,129.4,143.7,164.9,165.3,165.6,166.1,166.5ppm;MS(ESI)m/z(%):510[M+1]+;HRMS(ESI)calcd.for C21H26BrF3NO5[M+1]+:508.0941;found:508.0939.
实施例27
制备化合物7f:
无色液体;分离产率32%;IR(neat)v/cm-1:2956,2874,1763,1715,1602,1572,1455,1435,1293,1257,1197,1146,1084,1038,741;1H NMR(400MHz,CDCl3)δ1.39-1.51(m,3H),1.74-2.07(m,3.45H),2.36(dd,J=16.0,8.0Hz,0.55H),2.57(s,3H),2.61-2.68(m,1H),3.36-3.56(m,3H),3.79-3.80(m,3H),3.81-4.06(m,2H),4.30(t,J=8.0Hz,2H),7.22-7.24(m,2H),7.38(t,J=8.0Hz,1H),7.86(d,J=8.0Hz,1H);19F NMR(400MHz,CDCl3)δ-70.14(s,1.3F),-70.13(s,1.7F);13C NMR(400MHz,CDCl3)δ20.8,21.0,21.7,27.4,27.5,28.5,31.2,32.0,32.5,32.7,42.8,43.0,53.5,54.8,55.5,59.6(m),63.9,123.2(q,JCF=279Hz),123.7(q,JCF=280Hz),125.6,129.4,130.1,131.7,132.0,140.0,164.9,165.3,165.6,166.1,167.4;MS(ESI)m/z(%):510[M+1]+;HRMS(ESI)calcd.for C21H26BrF3NO5[M+1]+:508.0941;found:508.0933.
实施例28
制备化合物7g:
无色液体;分离产率41%;IR(neat)v/cm-1:2956,2865,2834,1758,1712,1606,1512,1435,1383,1257,1178,1103,1030,849,772,698,613;1H NMR(400MHz,CDCl3)δ1.35-1.50(m,3H),1.72-2.07(m,3.54H),2.34(dd,J=12.0,8.0Hz,0.66H),2.60-2.67(m,1H),3.32-3.52(m,3H),3.77(s,3H),3.81(s,3H),3.94-4.05(m,2H),4.23-4.32(m,2H),6.88(d,J=8.0Hz,2H),7.93(d,J=8.0Hz,2H);19F NMR(400MHz,CDCl3)δ-70.2(s,1.5F),-70.1(s,1.5F);13C NMR(400MHz,CDCl3)δ20.7,21.0,27.4,27.5,28.6,31.2,32.0,32.5,32.7,42.8,43.0,53.5,53.6,54.9,55.4,55.5,59.5(m),63.9,113.6,122.5,123.2(q,JCF=267Hz),123.7(q,JCF=277Hz),131.4,163.3,164.9,165.3,165.6,166.0,166.2;MS(ESI)m/z(%):526[M+1]+;HRMS(ESI)calcd.for C21H26BrF3NO6[M+1]+:524.0890;found:524.0885.
实施例29
制备化合物7h:
无色液体;分离产率41%;IR(neat)v/cm-1:2954,2867,1758,1713,1586,1434,1393,1278,1177,1103,1035,1008,923,847,755,683;1H NMR(400MHz,CDCl3)δ1.36-1.47(m,3H),1.75-1.93(m,3H),2.02(dd,J=16.0,8.0Hz,0.53H),2.34(dd,J=16.0,8.0Hz,0.47H),2.60-2.67(m,1H),3.35-3.44(m,2H),3.46-3.55(m,1H),3.79(s,3H),3.82-3.88(m,1H),3.97-4.06(m,1H),4.30(t,J=8.0Hz,2H),7.69(dd,J=8.4Hz,2.0Hz,2H),7.77(d,J=8.0Hz,2H);19F NMR(400MHz,CDCl3)δ-70.10(s,1.64F),-70.09(s,1.36F);13C NMR(400MHz,CDCl3)δ20.7,20.9,27.4,27.5,28.5,31.2,32.0,32.5,32.7,42.9,43.1,53.5,53.6,54.9,55.5,59.6(m),64.4,100.7,123.2(q,JCF=223Hz),123.7(q,JCF=225Hz),129.5,130.9,137.7,164.9,165.3,165.5,165.9,166.0;MS(ESI)m/z(%):622[M+1]+;HRMS(ESI)calcd.for C20H23BrIF3NO5[M+1]+:619.9751;found:619.9744.
实施例30
制备化合物7i:
无色液体;分离产率31%;IR(neat)v/cm-1:2956,2920,1759,1713,1594,1435,1322,1296,1277,1193,1169,1073,832,688;1H NMR(400MHz,CDCl3)δ1.80-1.94(m,1H),2.30(s,6H),2.39-2.46(m,1H),2.57-2.62(m,1H),2.73-2.83(m,1H),3.45-3.62(m,3H),3.80(s,1.19H),3.83(s,1.81H),4.04-4.17(m,4H),6.52(s,2H),6.64(s,1H);19F NMR(400MHz,CDCl3)δ-70.2(s,1.23F),-70.1(s,1.77F);13C NMR(400MHz,CDCl3)δ27.4,31.3,32.4,32.8,32.9,43.1,43.3,53.56,53.64,53.8,59.6(m),63.4,112.0,123.1,123.3(q,JCF=279Hz),123.7(q,JCF=281Hz),139.4,158.2,165.0,165.4,165.6,166.2;MS(ESI)m/z(%):466[M+1]+;HRMS(ESI)calcd.for C19H24BrF3NO4[M+1]+:466.0835;found:466.0831.
实施例31
制备化合物7j:
无色液体;分离产率33%;IR(neat)v/cm-1:2959,2863,1758,1711,1598,1435,1358,1276,1291,1283,1097,1035,967,923,816,737,664,555;1H NMR(400MHz,CDCl3)δ1.38-1.48(m,1H),1.52-1.59(m,2H),1.82-1.97(m,1.49H),2.26-2.31(dd,J=12.0,8.0Hz,0.51H),2.43(s,3H),2.56-2.63(m,1H),3.29-3.40(m,2H),3.45-3.54(m,1H),3.80-3.81(m,3H),3.96-4.08(m,3H),7.34(d,J=8.0Hz,2H),7.76(d,J=8.0Hz,2H);19F NMR(400MHz,CDCl3)δ-70.2(s,1.47F),-70.1(1.53F);13C NMR(400MHz,CDCl3)δ21.6,23.6,23.9,27.4,27.4,28.9,29.1,30.8,31.6,42.8,43.0,53.6,53.8,54.3,54.9,59.4(q,JCF=14Hz),69.4,123.2(q,JCF=279Hz),123.6(q,JCF=281Hz),127.8,130.0,145.1,164.9,165.3,165.4,166.0;MS(ESI)m/z(%):530[M+1]+;HRMS(ESI)calcd.for C19H24BrF3NO6S[M+1]+:530.0454;found:530.0450.
实施例32
制备化合物7k:
浅黄色液体;分离产率45%;IR(neat)v/cm-1:3061,2954,2869,1762,1712,1459,1428,1379,1334,1308,1193,1075,996,756,728,704,672;1H NMR(400MHz,CDCl3)δ:1.52-1.66(m,1H),1.80-1.88(m,2H),1.97-2.11(m,1.32H),2.36(dd,J=12.0Hz,4.0Hz,0.68H),2.63-2.71(m,1H),3.31-3.56(m,5H),3.77-3.79(m,3H),3.86-4.03(m,2H),7.28(t,J=8.0Hz,1H),7.39(t,J=8.0Hz,1H),7.73(d,J=8.0Hz,1H),7.83(d,J=8.0Hz,1H);19F NMR(400MHz,CDCl3)δ:-70.10(s,1.4F),-70.05(s,1.6F);13C NMR(400MHz,CDCl3)δ:24.1,24.3,27.4,27.5,31.1,31.6,31.9,32.6,42.8,43.1,53.5,53.6,54.5,55.0,59.6(m),121.0,123.2(q,JCF=280Hz),121.3,123.6(q,JCF=281Hz),126.0,136.1,152.9,164.9,165.3,165.5,165.9;MS(ESI)m/z(%):527[M+1]+;HRMS(ESI)calcd.for C19H21BrF3N2O3S2[M+1]+:525.0124;found:525.0117.Anal.Calcd for C19H20BrF3N2O3S2:C,43.43;H,3.84;N,5.33;Found:C,43.48;H,3.64;N,4.97.
在干燥的10mL Schlenk管中加入fac-Ir(ppy)3(6.5mg,2mol%),严格抽换氮气三次,在氮气条件下加入DMF(1mL),底物1(0.5mmol)和芳基炔8(1.0mmol),置于24瓦荧光灯照射下室温搅拌反应过夜。体系倒入水(20mL)和乙酸乙酯(20mL)中分液,水相用乙酸乙酯萃取三次(5mL×3),合并有机相,饱和食盐水洗三次(5mL×3),无水硫酸钠干燥,抽滤,硅胶柱层析得到产物。
实施例33
制备化合物9a:
浅黄色液体;分离产率59%;IR(neat)v/cm-1:3067,2956,2916,2882,1762,1666,1437,1276,1229,1182,1105,1031,925;1H NMR(400MHz,CDCl3)δ:3.48-3.54(m,2H),3.55(s,3H),3.86-3.91(m,2H),6.61(s,1H),7.30-7.39(m,5H);19F NMR(376MHz,CDCl3)δ-67.8(s);13C NMR(100MHz,CDCl3)δ53.6,54.1,60.3(q,JCF=27Hz),67.9,121.9,122.4(q,JCF=264Hz),127.7,128.8,128.9,129.1,137.1,158.7,163.5;MS(ESI)m/z(%):394[M+1]+;HRMS(ESI)calcd.for C15H14BrF3NO3[M+1]+:392.0104;found:392.0102.
实施例34
制备化合物9b:
无色液体;分离产率64%;IR(neat)v/cm-1:3072,2957,2908,2899,1762,1667,1599,1505,1439,1354,1319,1257,1186,1104,1032,936,842;1H NMR(400MHz,CDCl3)δ3.55-3.60(m,5H),3.91-3.99(m,2H),6.61(s,1H),7.02(t,J=8.8Hz,2H),7.36-7.40(m,2H);19F NMR(376MHz,CDCl3)δ-110.7(m,1F),-67.8(s,3F);13C NMR(100MHz,CDCl3)δ53.6,54.2,60.4(q,JCF=27Hz),68.1,114.7,114.9,122.4(q,JCF=274Hz),122.7,127.6,131.1,131.2,158.8,161.5,163.5,164.0;MS(ESI)m/z(%):412[M+1]+;HRMS(ESI)calcd.forC15H13BrF4NO3[M+1]+410.0009;found 410.0007.
实施例35
制备化合物9c:
浅黄色液体;分离产率64%;IR(neat)v/cm-1:3084,2956,2912,2890,1759,1667,1564,1436,1354,1254,1192,1109,1032,929;1H NMR(400MHz,CDCl3)δ3.47-3.54(m,2H),3.59(s,3H),3.89-4.01(m,2H),6.61(s,1H),6.95-7.07(m,1H),7.23-7.30(m,2H),7.34(s,1H);19F NMR(376MHz,CDCl3)δ-67.8(s);13C NMR(100MHz,CDCl3)δ53.6,54.2,60.3(q,JCF=22Hz),68.1,123.0,123.3(q,JCF=227Hz),126.7,127.2,128.9,129.15,129.18,133.5,138.7,158.6,163.3;MS(ESI)m/z(%):428[M+1]+;HRMS(ESI)calcd.for C15H13BrClF3NO3[M+1]+:425.9714;found:425.9705.
实施例36
制备化合物9d:
白色固体;熔点:115.2-117.5℃:分离产率52%;IR(neat)v/cm-1:3084,3037,2954,2877,1758,1666,1486,1435,1255,1187,1104,1031,836;1H NMR(400MHz,CDCl3)δ2.46-3.56(m,2H),3.60(s,3H),3.87-3.93(m,2H),6.63(s,1H),7.36-7.40(m,2H),7.44-7.47(m,4H)7.56-7.59(m,4H);19F NMR(376MHz,CDCl3)δ-67.7(s);13C NMR(100MHz,CDCl3)δ:53.7,54.2,60.4(q,JCF=27Hz),68.0,122.1,122.4(q,JCF=284Hz),126.3,127.0,127.9,128.6,129.0,129.5,137.0,139.9,141.9,158.7,163.6;MS(ESI)m/z(%):470[M+1]+;HRMS(ESI)calcd.for C21H18BrF3NO3[M+1]+:468.0417;found:468.0411.
实施例37
制备化合物9e:
浅黄色液体;分离产率33%;IR(neat)v/cm-1:2955,2933,2843,1757,1701,1603,1508,1435,1257,1173,1113,1031,840;1H NMR(400MHz,CDCl3)δ3.36-3.39(m,2H),3.46(s,3H),3.50-3.62(m,2H),3.80(s,3H),6.50(s,1H),6.84(d,J=8.8Hz,2H),7.23(d,J=8.8Hz,2H);19F NMR(376MHz,CDCl3)δ-67.8(s);13C NMR(100MHz,CDCl3)δ31.1,41.8,53.6,55.3,64.8(q,JCF=25Hz),113.5,122.5(q,JCF=284Hz),122.6,129.1,129.6,130.1,160.2,161.8,165.2;MS(ESI)m/z(%):422[M+1]+;HRMS(ESI)calcd.for C16H16BrF3NO4[M+1]+:422.0209;found:422.0203.
实施例38
制备化合物9f:
浅黄色液体;分离产率62%;IR(neat)v/cm-1:3075,2959,2907,2877,1760,1667,1484,1437,1327,1255,1167,1136,1073,1033,701;1H NMR(400MHz,CDCl3)δ3.51(t,J=9.2Hz,2H),3.55(s,3H),3.87-4.00(m,2H),6.67(s,1H),7.48(t,J=8.0Hz,1H),7.58(d,J=8.0Hz,2H),7.67(s,1H);19F NMR(376MHz,CDCl3)δ-67.8(s,3F),-62.8(s,3F);13C NMR(100MHz,CDCl3)δ53.6,54.1,60.4(q,JCF=27Hz),68.1,122.3(q,JCF=284Hz),123.4,123.6(q,JCF=271Hz),125.8,126.5,128.5,130.2,130.5,132.3,137.9,158.6,163.3;MS(ESI)m/z(%):462[M+1]+;HRMS(ESI)calcd.for C16H13BrF6NO3[M+1]+:459.9978;found:459.9972.
实施例39
制备化合物9g:
浅黄色固体;熔点:77.8-79.3℃:分离产率65%;IR(neat)v/cm-1:2962,2899,2869,1759,1666,1436,1364,1267,1202,1112,1032,926,827;1H NMR(400MHz,CDCl3)δ1.30(s,9H),3.42-3.52(m,2H),3.57(s,3H),3.81-3.91(m,2H),6.58(s,1H),7.31(d,J=8.4Hz,2H),7.34(d,J=8.8Hz,2H);19F NMR(376MHz,CDCl3)δ-67.8(s);13C NMR(100MHz,CDCl3)δ31.0,34.6,53.5,54.0,60.3(q,JCF=28Hz),67.7,121.6,122.4(q,JCF=284Hz),124.5,128.7,129.1,134.1,152.2,158.5,163.6;MS(ESI)m/z(%):450[M+1]+;HRMS(ESI)calcd.for C19H22BrF3NO3[M+1]+:448.0730;found:448.0724.
实施例40
制备化合物9h:
浅黄色液体;分离产率43%;IR(neat)v/cm-1:3075,2955,2916,2877,1758,1666,1584,1483,1436,1353,1104,1086,1032,1012,821;1H NMR(400MHz,CDCl3)δ3.42-3.54(m,2H),3.55(s,3H),3.86-3.96(m,2H),6.57(s,1H),7.22(d,J=8.8Hz,2H),7.43(d,J=8.4Hz,2H);19F NMR(376MHz,CDCl3)δ-67.8(s);13C NMR(100MHz,CDCl3)δ53.7,54.2,60.3(q,JCF=27Hz),68.1,122.3(q,JCF=274Hz),122.7,123.4,127.3,130.6,130.9,136.0,158.6,163.4;MS(ESI)m/z(%):472[M+1]+;HRMS(ESI)calcd.for C15H13Br2F3NO3[M+1]+469.9209,found 469.9205.
实施例41
制备化合物9i:
浅黄色液体;分离产率44%;IR(neat)v/cm-1:3088,2956,2920,2886,1759,1666,1591,1487,1436,1354,1256,1189,1104,1032,927,826;1H NMR(400MHz,CDCl3)δ3.42-3.52(m,2H),3.54(s,3H),3.86-3.97(m,2H),6.58(s,1H),7.24-7.30(m,4H);19F NMR(376MHz,CDCl3)δ-67.8(s);13C NMR(100MHz,CDCl3)δ53.6,54.1,60.3(q,JCF=27Hz),68.0,122.3(q,JCF=284Hz),122.7,127.2,127.9,130.4,136.1,136.5,158.6,163.4;MS(ESI)m/z(%):428[M+1]+;HRMS(ESI)calcd.for C15H13BrClF3NO3[M+1]+:425.9714,found:425.9706.
实施例42
制备化合物9j:
无色液体;分离产率67%;IR(neat)v/cm-1:3325,2936,2864,1757,1665,1436,1352,1253,1145,1092,1031,928,891,827;1H NMR(400MHz,CDCl3)δ1.52-1.58(m,2H),1.62-1.68(m,2H),1.98-2.06(m,2H),2.08-2.25(m,2H),3.80(s,3H),3.95(t,J=9.6Hz,2H),4.36(t,J=9.6Hz,2H),5.94(s,1H),6.26(s,1H);19F NMR(376MHz,CDCl3)δ-68.0(s);13C NMR(100MHz,CDCl3)δ21.3,22.1,25.1,26.1,53.6,54.4,59.7(q,JCF=27Hz),68.6,119.9,122.5(q,JCF=284Hz),130.8,133.8,134.5,160.4,163.9;MS(ESI)m/z(%):398[M+1]+;HRMS(ESI)calcd.for C15H18BrF3NO3[M+1]+:396.0417;found:396.0412.
实施例43
制备化合物9k:
浅黄色液体;分离产率63%;IR(neat)v/cm-1:3063,3028,2955,1759,1666,1603,1490,1472,1436,1351,1272,1189,1103,1031,948,864,700;1H NMR(400MHz,CDCl3)δ2.51(m,1H),3.01(dt,J=14.4,5.2Hz,1H),3.40(s,1.51H),3.44(s,1.49H),3.76-3.80(m,2H),4.03-4.11(m,1H),6.56(s,0.51H),6.69(s,0.49H),7.11-7.24(m,4H),7.28-7.42(m,6H);19F NMR(376MHz,CDCl3)δ-67.8(s,1.5F),-67.7(s,1.5F);13C NMR(100MHz,CDCl3)δ40.4,40.6,53.2,53.3,60.2(m),67.0,67.1,71.9,72.4,122.1,122.2,122.3(q,JCF=284Hz),122.5(q,JCF=284Hz),126.5,127.79,127.82,128.4,128.6,128.8,128.9,129.0,129.1,129.13,129.16,129.3,136.9,137.0,137.09,137.11,158.3,158.7,136.27,163.33;MS(ESI)m/z(%):484[M+1]+;HRMS(ESI)calcd.for C22H20BrF3NO3[M+1]+:482.0573,found:482.0566.
实施例44
制备化合物9l:
浅黄色液体;分离产率43%;IR(neat)v/cm-1:3071,3032,2968,2916,1755,1664,1493,1436,1352,1273,1236,1174,1104,1030,775,700;1H NMR(400MHz,CDCl3)δ3.44(s,1.51H),3.46(s,1.49H),3.94(t,J=8.4Hz,0.51H),4.04(t,J=8.4Hz,0.51H),4.23(t,J=8.8Hz,0.49H),4.29(t,J=9.6Hz,0.49H),4.83-4.91(m,1H),6.59(s,0.51H),6.81(s,0.49H),7.13-7.19(m,2H),7.28-7.44(m,8H);19F NMR(376MHz,CDCl3)δ-67.64(s,1.5F),-67.59(s,1.5F);13C NMR(100MHz,CDCl3)δ53.3,53.4,60.6(m),69.2,69.4,75.3,75.8,122.0,122.1,122.3(q,JCF=284Hz),122.7(q,JCF=284Hz),126.4,126.6,127.8,127.9,128.7,128.9,129.1,129.17,129.20,137.0,141.0,141.1,159.3,160.0,163.3;MS(ESI)m/z(%):468[M+1]+;HRMS(ESI)calcd.for C21H18BrF3NO3[M+1]+:468.0417,found:468.0412.
实施例45
制备化合物9m:
浅黄色液体;分离产率53%;IR(neat)v/cm-1:3066,2970,2932,2899,1758,1665,1490,1463,1444,1367,1351,1289,1210,1172,1104,1031,919,871,767,701;1H NMR(400MHz,CDCl3)δ1.20(s,6H),3.27(s,3H),3.78(q,J=8.4Hz,2H),6.65(s,1H),7.31-7.39(m,5H);19F NMR(376MHz,CDCl3)δ:-68.0(s);13C NMR(100MHz,CDCl3)δ27.4,27.5,53.0,60.1(q,JCF=27Hz),67.8,79.5,122.5(q,JCF=284Hz),122.6,127.9,128.5,129.0,129.2,137.3,157.1,163.3;MS(ESI)m/z(%):422[M+1]+;HRMS(ESI)calcd.for C17H18BrF3NO3[M+1]+:420.0417,found:420.0406.
实施例46
制备化合物9n:
无色液体;分离产率56%;IR(neat)v/cm-1:3066,2957,2872,1760,1663,1589,1490,1469,1436,1368,1256,1174,1105,1031,939,864,766,700;1H NMR(400MHz,CDCl3)δ0.86-0.91(m,6H),1.12-1.20(m,1H),1.47-1.52(m,1H),1.60-1.67(m,1H),3.40(s,1.49H),3.43(s,1.51H),3.66(q,J=8.0Hz,1H),3.78-3.87(m,1H),3.95-4.00(m,1H),6.56(s,0.51H),6.69(s,0.49H),7.30-7.41(m,5H);19F NMR(376MHz,CDCl3)δ-67.9(s,1.4F),-67.8(s,1.6F);13C NMR(100MHz,CDCl3)δ22.3,22.4,22.8,22.9,25.1,25.2,44.3,44.4,53.2,60.2(m),64.6,64.8,73.4,73.6,122.3(q,JCF=284Hz),122.3,122.4,122.6(q,JCF=284Hz),127.7,127.8,128.5,128.6,128.9,129.00,129.04,129.1,137.2,157.5,157.9,163.4;MS(ESI)m/z(%):450[M+1]+;HRMS(ESI)calcd.for C19H22BrF3NO3[M+1]+:448.0730,found:448.0717.
实施例47
制备化合物9o:
浅黄色液体;分离产率31%;IR(neat)v/cm-1:3058,2960,2908,2869,1761,1668,1436,1350,1252,1173,1104,1030,947,767,700;1H NMR(400MHz,CDCl3)δ0.82(dd,J=6.8,3.6Hz,3H),0.87(t,J=6.8Hz,3H),1.68-1.79(m,1H),3.34(s,1.51H),3.39(s,1.49H),3.61-3.72(m,1H),3.79-3.90(m,2H),6.55(s,0.49H),6.73(s,0.51H),7.30-7.34(m,4H),7.39-7.41(m,1H);19F NMR(376MHz,CDCl3)δ-67.81(s,1.5F),-67.78(s,1.5F);13C NMR(100MHz,CDCl3)δ17.3,17.5,18.3,18.4,31.8,32.0,53.1,60.2(m),70.1,70.6,71.6,71.7,122.3(q,JCF=284Hz),122.3,122.5,122.6(q,JCF=284Hz),127.7,127.8,128.4,128.6,128.9,129.0,129.1,137.09,137.14,157.7,158.2,163.4,163.5;MS(ESI)m/z(%):436[M+1]+;HRMS(ESI)calcd.for C18H20BrF3NO3[M+1]+:434.0573,found:434.0566.
实施例48
制备化合物9p:
浅黄色液体;分离产率53%;IR(neat)v/cm-1:3066,2962,2903,2878,1761,1668,1489,1436,1351,1255,1185,1105,1031,941,864,766,700;1H NMR(400MHz,CDCl3)δ0.75(t,J=6.4Hz,3H),0.88(dt,J=7.2,3.2Hz,3H),1.06-1.17(m,1.51H),1.25-1.41(m,1.49H),3.36(s,1.49H),3.40(s,1.51H),3.71-3.90(m,3H),6.54(s,0.49H),6.73(s,0.51H),7.28-7.37(m,4H),7.40-7.42(m,1H);19F NMR(376MHz,CDCl3)δ-67.8(s);13C NMR(100MHz,CDCl3)δ11.5,13.5,13.7,25.9,38.0,38.2,53.1,60.1(m),69.4,70.0,70.1,70.3,122.3(m),122.6(q,JCF=284Hz),127.7,127.8,128.4,128.6,128.9,128.99,129.04,129.06,137.0,137.1,157.5,158.0,163.3,163.4ppm;MS(ESI)m/z(%):450[M+1]+;HRMS(ESI)calcd.for C19H22BrF3NO3[M+1]+:448.0730,found:448.0720.
生物活性测试
对上述合成的产物,委托沈阳中化农药化工研发有限公司对其杀菌、杀虫以及除草的生物活性进行了测试。经过对黄瓜霜霉病、黄瓜炭疽病、小麦白粉病、玉米锈病、小菜蛾、粘虫、桃蚜、朱砂叶螨、百日草、苘麻、金狗尾和稗草的测试,发现化合物3i对小麦白粉病和玉米锈病具有一定的防治效果,化合物7a对黄瓜霜霉病、小麦白粉病和黄瓜炭疽病具有一定的防治效果。具体情况如下:
1杀菌活性结果
测试结果表明,化合物3i对小麦白粉病和玉米锈病具有一定的防治效果,化合物7a对黄瓜霜霉病、小麦白粉病和黄瓜炭疽病具有一定的防治效果,其它化合物在试验剂量下,活性不明显,结果见表1。
表1 杀菌活性活性测试结果
2杀虫活性结果
测试结果表明,在试验剂量下,3g等5个化合物对小菜蛾、粘虫、桃蚜和朱砂叶螨的活性不明显,结果见表2。
表2 杀虫活性活性测试结果
3除草活性结果
测试结果表明,在试验剂量下,3g等5个化合物对百日草、苘麻、金狗尾和稗草的活性不明显,结果见表3。
表3 除草活性活性测试结果
Claims (24)
1.一种如式3或3’所示的三氟甲基季碳中心化合物,
其中X为卤素;m为1、2、3、4或5;
R1为H、取代或未取代的C1~6烷基;
R2为H、取代或未取代的C1~6烷基;
R3为取代或未取代的C1~6烷氧基、取代或未取代的C6~10环烷氧基、芳香烃硫基、n为1、2、3、4或5。
2.如权利要求1所述的三氟甲基季碳中心化合物,其特征在于,所述的卤素为F、Cl、Br或I;
和/或,所述的R1为H、甲基或乙基,较佳地为H或甲基;
和/或,所述的R2为H、甲基或乙基,较佳地为H或甲基;
和/或,所述的C1~6烷氧基为甲氧基、乙氧基、丙氧基或丁氧基,较佳地为OEt、OiPr、OtBu或OnBu;
和/或,所述的C6~10环烷氧基为
和/或,所述的芳香烃硫基为SPh。
3.如权利要求1所述的三氟甲基季碳中心化合物,其特征在于,所述的如式3或3’所示的三氟甲基季碳中心化合物为如下任一化合物:
4.一种如权利要求1~3中任一项所述的三氟甲基季碳中心化合物的制备方法,其包括下述步骤:
有机溶剂中,在催化剂的作用下,化合物1与化合物2或2’反应,即可得到化合物3或3’;
m、X、R1、R2、R3的定义均同权利要求1~3中至少一项所述。
5.如权利要求4所述的制备方法,其特征在于,所述的有机溶剂为二甲基甲酰胺、苯、甲苯、N-甲基吡咯烷酮和四氯化碳中的一种或多种,较佳地为二甲基甲酰胺;
和/或,所述的催化剂为金属络合物催化剂,较佳地为Ru(bpy)3(PF6)2、fac-Ir(ppy)3、Ir(bpy)2(dtbbpy)(PF6)、Ir(dF(CF3)ppy)2(dtbbpy)(PF6),更佳地为Ir(dF(CF3)ppy)2(dtbbpy)(PF6);
和/或,所述的反应为在可见光辐照下进行的反应,较佳地为在荧光辐照下进行的反应;
和/或,所述的反应的温度为15~30℃;
和/或,所述的化合物1与所述的化合物2或2’的摩尔比为1∶(1~10);
和/或,所述的反应的时间为1分钟~1小时,较佳地为10分钟~1小时。
6.一种如权利要求1~3中任一项所述的三氟甲基季碳中心化合物在制备治疗和/或预防植物疾病的药物中的应用;所述的植物疾病较佳地包括黄瓜霜霉病、小麦白粉病、黄瓜炭疽病、玉米锈病中的一种或多种。
7.一种如式5所示的三氟甲基季碳中心化合物,
其中X为卤素;
R1为H、取代或未取代的C1~6烷基;
R2为H、取代或未取代的C1~6烷基;
R4为H、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的蒽基;
R5为H、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的蒽基;
R4与R5不同时为H。
8.如权利要求7所述的三氟甲基季碳中心化合物,其特征在于,
所述的卤素为F、Cl、Br或I;
和/或,所述的R1为H、甲基或乙基,较佳地为H或甲基;
和/或,所述的R2为H、甲基或乙基,较佳地为H或甲基;
和/或,所述的取代或未取代的苯基较佳地为其中R6为H、C1~6烷基、C1~6烷氧基、C6~10环烷氧基、卤素、乙酰氧基或苯基;R6中所述的C1~6烷基较佳地为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基,R6中所述的C1~6烷氧基较佳地为甲氧基、乙氧基、OiPr、OtBu或OnBu,R6中所述的C6~10环烷氧基较佳地为
9.如权利要求7所述的三氟甲基季碳中心化合物,其特征在于,所述的如式5所示的三氟甲基季碳中心化合物为如下任一化合物:
10.一种如权利要求7~9中任一项所述的三氟甲基季碳中心化合物的制备方法,其包括下述步骤:
有机溶剂中,在催化剂的作用下,化合物1与化合物4反应,即可得到化合物5;
X、R1、R2、R4、R5的定义均同权利要求7~9中至少一项所述。
11.如权利要求10所述的制备方法,其特征在于,所述的有机溶剂为二甲基甲酰胺、苯、甲苯、N-甲基吡咯烷酮和四氯化碳中的一种或多种,较佳地为二甲基甲酰胺;
和/或,所述的催化剂为金属络合物催化剂,较佳地为Ru(bpy)3(PF6)2、fac-Ir(ppy)3、Ir(ppy)2(dtbbpy)(PF6)、Ir(dF(CF3)ppy)2(dtbbpy)(PF6),更佳地为Ir(ppy)2(dtbbpy)(PF6);
和/或,所述的反应为在可见光辐照下进行的反应,较佳地为在荧光辐照下进行的反应;
和/或,所述的反应的温度为15~30℃;
和/或,所述的化合物1与所述的化合物4的摩尔比为1∶(1~10);
和/或,所述的反应的时间为1分钟~20小时,较佳地为10小时~20小时。
12.一种如权利要求7~9中任一项所述的三氟甲基季碳中心化合物在制备治疗和/或预防植物疾病的药物中的应用;所述的植物疾病较佳地包括黄瓜霜霉病、小麦白粉病、黄瓜炭疽病、玉米锈病中的一种或多种。
13.一种如式7所示的三氟甲基季碳中心化合物,
其中X为卤素;
R1为H、取代或未取代的C1~6烷基;
R2为H、取代或未取代的C1~6烷基;
R7为C1~10烷基、 n为1、2、3、4或5,R8为H、C1~6烷基、C1~6烷氧基、C6~10环烷氧基、卤素、三氟甲基或氰基;R9为H、C1~6烷基、C1~6烷氧基、C6~10环烷氧基、卤素、三氟甲基或氰基。
14.如权利要求13所述的三氟甲基季碳中心化合物,其特征在于,
所述的卤素为F、Cl、Br或I;
和/或,所述的R1为H、甲基或乙基,较佳地为H或甲基;
和/或,所述的R2为H、甲基或乙基,较佳地为H或甲基;
和/或,所述的C1~10烷基为C6~10烷基,较佳地为-C8H17;
和/或,R8或R9中所述的C1~6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基,R8或R9中所述的C1~6烷氧基为甲氧基、乙氧基、OiPr、OtBu或OnBu,R8或R9中所述的C6~10环烷氧基为
15.如权利要求13所述的三氟甲基季碳中心化合物,其特征在于,所述的如式7所示的三氟甲基季碳中心化合物为如下任一化合物:
16.一种如权利要求13~15中任一项所述的三氟甲基季碳中心化合物的制备方法,其包括下述步骤:
有机溶剂中,在催化剂的作用下,化合物1与化合物6反应,即可得到化合物7;
X、R1、R2、R7的定义均同权利要求13~15中至少一项所述。
17.如权利要求16所述的制备方法,其特征在于,
所述的有机溶剂为二甲基甲酰胺、苯、甲苯、N-甲基吡咯烷酮和四氯化碳中的一种或多种,较佳地为二甲基甲酰胺;
和/或,所述的催化剂为金属络合物催化剂,较佳地为Ru(bpy)3(PF6)2、[Ir(bpy)3Cl]2、Ir(bpy)2(dtbbpy)(PF6)、Ir(ppy)2(dtbbpy)(PF6)、Ir(dF(CF3)ppy)2(dtbbpy)(PF6)、fac-Ir(ppy)3,更佳地为fac-Ir(ppy)3;
和/或,所述的反应为在可见光辐照下进行的反应,较佳地为在荧光辐照下进行的反应;
和/或,所述的反应的温度为15~30℃;
和/或,所述的化合物1与所述的化合物6的摩尔比为1∶(1~10);
和/或,所述的反应的时间为1分钟~20小时,较佳地为10小时~20小时。
18.一种如权利要求13~15中任一项所述的三氟甲基季碳中心化合物在制备治疗和/或预防植物疾病的药物中的应用;所述的植物疾病较佳地包括黄瓜霜霉病、小麦白粉病、黄瓜炭疽病、玉米锈病中的一种或多种。
19.一种如式9所示的三氟甲基季碳中心化合物,
其中X为卤素;
R1为H、取代或未取代的C1~6烷基、苯基、甲苯基或苯甲基;
R2为H、取代或未取代的C1~6烷基、苯基、甲苯基或苯甲基;
R10为C6~10烯基、R11为H、C1~6烷基、C1~6烷氧基、C6~10环烷氧基、苯基、卤素、氰基或三氟甲基。
20.如权利要求19所述的三氟甲基季碳中心化合物,其特征在于,
所述的卤素为F、Cl、Br或I;
和/或,所述的R1为H、甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、苯基、甲苯基或苯甲基;
和/或,所述的R2为H、甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、苯基、甲苯基或苯甲基;
和/或,所述的C6~10烯基为
和/或,R11中所述的C1~6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基,R11中所述的C1~6烷氧基为甲氧基、乙氧基、OiPr、OtBu或OnBu,R11中所述的C6~10环烷氧基为
21.如权利要求19所述的三氟甲基季碳中心化合物,其特征在于,所述的如式9所示的三氟甲基季碳中心化合物为如下任一化合物:
22.一种如权利要求19~21中任一项所述的三氟甲基季碳中心化合物的制备方法,其包括下述步骤:
有机溶剂中,在催化剂的作用下,化合物1与化合物8反应,即可得到化合物9;
X、R1、R2、R10的定义均同权利要求19~21中至少一项所述。
23.如权利要求22所述的制备方法,其特征在于,所述的有机溶剂为二甲基甲酰胺、二甲基乙酰胺、二甲基亚砜、CH3CN、CH3NO2、N-甲基吡咯烷酮和四氯化碳中的一种或多种,较佳地为二甲基甲酰胺;
和/或,所述的催化剂为金属络合物催化剂,较佳地为Ru(bpy)3Cl2、Ru(bpy)3(PF6)2、[Ir(bpy)3Cl]2、Ir(bpy)2(dtbbpy)(PF6)、Ir(ppy)2(dtbbpy)(PF6)、Ir(dF(CF3)ppy)2(dtbbpy)(PF6)、fac-Ir(ppy)3,更佳地为fac-Ir(ppy)3;
和/或,所述的反应为在可见光辐照下进行的反应,较佳地为在荧光辐照下进行的反应;
和/或,所述的反应的温度为15~30℃;
和/或,所述的化合物1与所述的化合物8的摩尔比为1∶(1~10);
和/或,所述的反应的时间为1分钟~20小时,较佳地为10小时~20小时。
24.一种如权利要求19~21中任一项所述的三氟甲基季碳中心化合物在制备治疗和/或预防植物疾病的药物中的应用;所述的植物疾病较佳地包括黄瓜霜霉病、小麦白粉病、黄瓜炭疽病、玉米锈病中的一种或多种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610402650.8A CN107474004B (zh) | 2016-06-07 | 2016-06-07 | 三氟甲基季碳中心化合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610402650.8A CN107474004B (zh) | 2016-06-07 | 2016-06-07 | 三氟甲基季碳中心化合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107474004A true CN107474004A (zh) | 2017-12-15 |
CN107474004B CN107474004B (zh) | 2022-07-19 |
Family
ID=60594535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610402650.8A Expired - Fee Related CN107474004B (zh) | 2016-06-07 | 2016-06-07 | 三氟甲基季碳中心化合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107474004B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044813A1 (en) * | 2003-11-11 | 2005-05-19 | Shenyang Research Institute Of Chemical Industry | Benzopyrone compounds, preparation method and use thereof |
WO2005080344A1 (fr) * | 2004-02-20 | 2005-09-01 | Shenyang Research Institute Of Chemical Industry | Compose d'azole substitue et preparation et application correspondantes |
CN101133022A (zh) * | 2004-07-12 | 2008-02-27 | 拜尔农作物科学股份公司 | 用作杀真菌剂和杀虫剂的取代的2-吡咯烷酮衍生物 |
-
2016
- 2016-06-07 CN CN201610402650.8A patent/CN107474004B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044813A1 (en) * | 2003-11-11 | 2005-05-19 | Shenyang Research Institute Of Chemical Industry | Benzopyrone compounds, preparation method and use thereof |
WO2005080344A1 (fr) * | 2004-02-20 | 2005-09-01 | Shenyang Research Institute Of Chemical Industry | Compose d'azole substitue et preparation et application correspondantes |
CN101133022A (zh) * | 2004-07-12 | 2008-02-27 | 拜尔农作物科学股份公司 | 用作杀真菌剂和杀虫剂的取代的2-吡咯烷酮衍生物 |
Non-Patent Citations (2)
Title |
---|
任玮静等: "嘧啶类杀菌剂的研究进展", 《农药》 * |
司乃国等: "创制杀菌剂烯肟菌酯生物活性及应用( Ⅱ) ———小麦白粉病", 《农药》 * |
Also Published As
Publication number | Publication date |
---|---|
CN107474004B (zh) | 2022-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2331001T3 (es) | Forma cristalina de linezolid. | |
JP6995178B2 (ja) | 細胞毒性ベンゾジアゼピン誘導体の調製方法 | |
BR112014020444A2 (pt) | Processo para a preparação de (s)-1-(3-etoxi-4-metoxifenil)-2-metanossulfoniletilamina ecomposto | |
CN106883114A (zh) | 一种芴类多官能度光引发剂及其制备和应用 | |
US20200324272A1 (en) | Method for hydrophobization of hydrophilic material | |
JP2022105096A (ja) | 細胞傷害性ベンゾジアゼピン誘導体の調製方法 | |
HUE026880T2 (en) | Procedures for the preparation of HIV binding inhibitor prodrug compound and intermediate products | |
CN110078621B (zh) | 1,3-环二酮烯醇醚化合物、1-不对称供体受体环丙烷以及它们的合成方法 | |
CN105085303B (zh) | 季铵盐化合物、其制备方法和作为催化剂在酰氯制备中的用途 | |
CN102153501B (zh) | 手性含氮杂环化合物、合成方法及用途 | |
CN107474004A (zh) | 三氟甲基季碳中心化合物及其制备方法和应用 | |
CN105148988A (zh) | 一种手性吡哆醛类催化剂及其合成方法与应用 | |
FR2440352A1 (fr) | Procede de preparation d'un derive de l'acide phenoxycarboxylique par reaction d'un compose du phenol et d'un compose halogene | |
ES2612919T3 (es) | Procedimiento de preparación de cloraminas | |
WO2017027435A1 (en) | Protected organoboronic acids with tunable reactivity, and methods of use thereof | |
ES2354355T3 (es) | Procedimento para la cloración de alcoholes terciarios. | |
Neverov et al. | X+ transfer from the halonium ions of adamantylideneadamantane to acceptor olefins. The possibility of chiral induction in the transfer process | |
Omelanczuk et al. | Stereochemistry of nucleophilic substitution at the optically active trivalent phosphorus atom | |
CN104650357A (zh) | 包含含氮有机氧基硅烷化合物的组合物及其制备方法 | |
CN104761559B (zh) | 一种六氢吡咯并[3,4‑c]吡咯烷类化合物及其制备方法 | |
CN109336845A (zh) | 光学活性环戊烷-3-亚胺及其衍生物和制备方法 | |
CN106187840A (zh) | 一种带三氟甲硫基的茚酮类化合物及其制备方法 | |
US6359174B1 (en) | Lewis acid-catalyzed claisen rearrangement in the preparation of chiral products | |
JPH04224560A (ja) | ベンジルアルコール誘導体及びそれを有効成分とする除草剤 | |
BR112020007197A2 (pt) | novo processo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220719 |